SCODiA Report by MLBI Lab

Single-Cell Transcriptomic Analysis of Pancreatic Dysfunction in Type 2 Diabetes and Prediabetes

This report provides a comprehensive single-cell transcriptomic analysis of the human pancreas across non-diabetic, prediabetic, and type 2 diabetic conditions. While cell type identity remains the primary determinant of the transcriptional landscape, significant molecular shifts occur within existing cell populations during disease progression. Key findings include evidence of pronounced ER stress and apoptosis in Beta cells, a clear pro-inflammatory shift in pancreatic macrophages, and indicators of fibrosis in pancreatic stellate cells. Altered cell-cell communication networks, involving pathways like LCN2-SLC2A1, BMP5, and Desmosterol-LXRB, also contribute to pancreatic dysfunction.

Contents

0. Dataset overview
1. UMAP Visualization of Pancreatic Single-Cell Data by Condition, Sample, and Cell Type
2. Cell Type Score Visualization on UMAP Embedding
3. Marker Expression and Annotation Quality Assessment for Pancreatic Cell Subsets
4. Pancreatic Minor Cell Type Population Dynamics Across Diabetic Conditions
5. Pancreatic Macrophage Subset Composition Across Diabetes Progression
6. Cell-Cell Interaction Patterns in Human Pancreas Across Diabetes Conditions
7. Condition-Specific Cell-Cell Interaction Patterns in Pancreatic Cells Across Diabetic States
8. Beta Cell Condition-Specific Surfaceome Marker Analysis in Type 2 Diabetes
9. Analysis of Macrophage Condition-Specific Surfaceome Markers in Pancreatic Diabetes
10. Pancreatic Stellate Cell Surfaceome Markers in Type 2 Diabetes
11. Gene Ontology (GSA) Analysis of Beta Cells Across Diabetes Conditions
12. Gene Set Enrichment Analysis Reveals Cell Type-Specific Metabolic and Inflammatory Dysregulation in Pancreatic Cells of Prediabetes and Type 2 Diabetes
13. Discussion
14. Query List

0. Dataset overview

Dataset Summary:

• This AnnData object contains single-cell RNA-seq data for 90,006 cells and 28,920 genes from human Pancreas tissue.
• Key observational metadata (.obs) columns include: sample, condition (type2_diabetes, non_diabetic, prediabetes), sample_title, accession, tissue, disease_state, sample_ext, and hierarchical cell type annotations (celltype_major, celltype_minor, celltype_subset), as well as cluster.
• Gene-level metadata (.var) includes: gene_symbol, feature_type, gene_id, and variable_genes.
• Tumor identification was not requested for this dataset, and CNV estimates are not available.
• The reference condition for differential expression and enrichment analyses is 'non_diabetic'.
• Precomputed results stored in uns include:
• CCI: Cell-cell interaction results (CellPhoneDB) per condition.
• CCI_sample: Cell-cell interaction results (CellPhoneDB) per sample.
• DEG: Differential expression gene results per celltype_minor (condition vs. rest).
• DEG_vs_ref: Differential expression gene results per celltype_minor (condition vs. reference).
• GSEA: Gene Set Enrichment Analysis results per celltype_minor (condition vs. rest).
• GSEA_vs_ref: GSEA results per celltype_minor (condition vs. reference).
• GSA_up: Gene Set Analysis (GO) results per celltype_minor (condition vs. rest).
• GSA_vs_ref_up: Gene Set Analysis (GO) results per celltype_minor (condition vs. reference).
• The inferred biological context is Type 2 Diabetes and Prediabetes, based on the conditions and tissue metadata.

1. UMAP Visualization of Pancreatic Single-Cell Data by Condition, Sample, and Cell Type

[Analysis Visualization Results]...

Analysis Overview

This analysis presents five UMAP (Uniform Manifold Approximation and Projection) plots, providing a comprehensive visual overview of the single-cell RNA-sequencing data from the human Pancreas. The UMAPs display the relationships between 90,006 cells across various biological annotations: condition (non_diabetic, prediabetes, type2_diabetes), sample, celltype_major, celltype_minor, and celltype_subset. These visualizations are crucial for assessing data quality, identifying batch effects, and evaluating the distinctness and distribution of cell populations and disease states within the dataset.

Visual Summary

Condition UMAP

The UMAP colored by condition (non_diabetic, prediabetes, type2_diabetes) shows a substantial overlap and intermingling of cells from all three conditions across the manifold. While there isn't clear, distinct clustering solely driven by disease status, there appear to be subtle gradients or enrichments. Specifically, 'type2_diabetes' cells (dark blue) and 'prediabetes' cells (light yellow) seem to be somewhat more concentrated in certain areas of the UMAP, particularly within or adjacent to clusters that might represent endocrine cell types, though a definitive separation is not observed. 'Non_diabetic' cells (dark red) are broadly distributed throughout the entire landscape. This intermingling suggests that while disease may induce gene expression changes, the fundamental cell type identities remain largely preserved, or that disease-specific changes are continuous rather than forming entirely new, separate cell populations in this embedding.

Sample UMAP

The sample UMAP displays a diverse array of colors (representing individual samples) generally well-mixed across most of the cell clusters. This indicates effective integration and batch correction, as cells from individual samples do not predominantly form their own isolated clusters. A good intermixing of samples is critical for ensuring that observed biological differences are not artifacts of technical variation. Some subtle regional enrichments of specific samples might be present, but the overall impression is that batch effects are minimal, allowing for robust comparisons across biological conditions and cell types.

Celltype_major UMAP

This UMAP clearly demonstrates that the most prominent feature driving the overall structure of the embedding is celltype_major. Distinct, well-separated clusters correspond to major pancreatic cell types such as Acinar cells (dark red), Alpha cells (red-orange), Beta cells (orange), Ductal cells (light orange), and Stromal cells (dark blue), among others. This strong separation confirms that the UMAP effectively captures the primary biological differences between these major cell populations, and that the cell type annotations are robust and consistent with the underlying gene expression profiles. The 'unassigned' cells are sparsely distributed, suggesting that most cells have been confidently assigned a major cell type.

Celltype_minor UMAP

The celltype_minor UMAP provides a more refined view of cell populations. While maintaining the overall structure seen in celltype_major, several larger celltype_major clusters now show further sub-division into celltype_minor populations. For example, the broad "Stromal cell" cluster from celltype_major is resolved into finer types like Stellate cells, Smooth muscle cells (SMC), and Fibroblasts (Fib). Similarly, "Myeloid cell" is refined to Macrophage (Mac). This indicates that the minor cell type annotations successfully identify more granular cell populations within the major cell lineages, revealing increased cellular heterogeneity.

Celltype_subset UMAP

The celltype_subset UMAP offers the highest resolution of cell identity. Here, even finer distinctions are made, such as the further sub-classification of Macrophages into M1, M2A, M2B, M2C, and M2D subtypes, and Endothelial cells into Endothelial (general), Endothelial tip cell, and Lymphatic Endothelial cell. This level of detail further confirms the extensive cellular heterogeneity within the Pancreas and demonstrates the ability of the clustering and annotation pipeline to resolve very specific cell states or subtypes. The distinct clustering of these subsets indicates meaningful biological differences at this granular level.

Biological Interpretation

The UMAP visualizations consistently demonstrate that cell type identity is the primary determinant of the transcriptional landscape in this pancreatic single-cell dataset. The clear separation of major, minor, and subset cell types across the UMAPs indicates high-quality cell type annotation based on distinct gene expression profiles.

The observation that cells from 'non_diabetic', 'prediabetes', and 'type2_diabetes' conditions largely intermingle suggests that while these conditions involve significant physiological changes in the Pancreas, they may not lead to the emergence of entirely novel, transcriptionally distinct cell types that would clearly separate on a UMAP plot. Instead, disease progression likely involves more subtle shifts in gene expression within existing cell types, changes in cell proportions, or altered functional states that are not captured as discrete clusters in this general embedding. The slight regional enrichments of diseased conditions warrant further investigation via differential expression analysis to identify specific genes and pathways altered within each cell type.

The good mixing of cells from different samples across the UMAPs is a positive indicator, suggesting that potential batch effects, which could confound biological interpretation, have been adequately addressed or were minimal. This strengthens the reliability of downstream analyses such as differential gene expression or cell-cell communication.

The hierarchical resolution of cell types from celltype_major to celltype_minor and celltype_subset is particularly valuable. For instance, the ability to distinguish various macrophage subtypes (M1, M2A-D) highlights the immune complexity within the pancreatic microenvironment, which is highly relevant to diabetes pathophysiology (e.g., inflammation in islet dysfunction) PubMed search: pancreatic macrophage type 2 diabetes. Similarly, the identification of different endothelial cell subsets suggests diverse vascular functions within the Pancreas, which can be critical for islet function and nutrient supply.

Annotation Notes

The UMAP plots provide strong evidence for the robustness and high resolution of the cell type annotations provided in the AnnData object.

• Cell Type Resolution: The distinct clustering observed from celltype_major down to celltype_subset confirms that the annotation strategy successfully captures the known cellular heterogeneity of the Pancreas. This hierarchical annotation allows for analyses at different levels of granularity, from broad cell lineages to highly specific cell subtypes and functional states.
• Data Integration Quality: The well-interspersed sample clusters indicate a successful integration of data across multiple donors, minimizing technical variation and maximizing the confidence in biological comparisons.
• Disease Representation: While disease conditions are largely intermingled, this is not necessarily an annotation issue. It suggests that the disease phenotype is likely driven by subtler gene expression changes within established cell types rather than by gross changes in cell identity or the appearance of entirely new cell populations. Subsequent analyses, such as differential gene expression or pathway enrichment, will be critical to uncover these condition-specific molecular changes within each cell type.
• 'unassigned' Cells: The limited number of 'unassigned' cells, visually distributed across different regions of the UMAPs, suggests that the majority of cells have been confidently classified. Further investigation into these 'unassigned' cells might be warranted if they form a distinct cluster.

2. Cell Type Score Visualization on UMAP Embedding

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a series of UMAP (Uniform Manifold Approximation and Projection) plots visualizing single-cell RNA-seq data from the human Pancreas. Each plot displays the enrichment score for a specific major cell type (HiCAT_major_score) across the UMAP embedding, using a color gradient from purple (low score) to yellow (high score). The final UMAP plot displays the discrete celltype_major annotations, which serve as a reference for validating the cell type scores. The objective is to visually assess the quality of cell type assignments and the overall structure of the single-cell landscape.

Visual Summary

The UMAP embedding shows a complex, multi-lobed structure representing the diverse cell populations within the pancreas.

Distinct Cell Clusters:

• Exocrine Pancreas: A large, distinct cluster in the bottom-right of the UMAP is strongly enriched for Acinar cells, matching the dark red 'Acinar' cluster in the celltype_major plot.
• Endocrine Pancreas (Islets of Langerhans): Several interconnected clusters in the central and top-right regions show high scores for Alpha cell, Beta cell, Delta cell, Gamma (PP) cell, and Epsilon cell. These regions correspond well to their respective color-coded clusters (orange, light orange, peach, dark green, light green) in the celltype_major plot, indicating successful separation of the various islet cell types.
• Ductal System: A large, prominent cluster in the upper-left region of the UMAP is highly enriched for Ductal cell scores, consistent with the yellow 'Ductal' cluster.

Stromal and Immune Cells:

• Stromal cell scores show enrichment in several peripheral regions, including areas adjacent to Acinar and Ductal cells, aligning with the light blue 'Stromal cell' cluster, suggesting heterogeneity within stromal compartments.
• Endothelial cell scores are enriched in a somewhat dispersed pattern, forming small clusters and streams within the UMAP, corresponding to the lime green 'Endo' cluster.
• Myeloid cell scores indicate a concentrated cluster towards the bottom-left of the main structure, which aligns with the teal 'Myeloid cell' cluster.
• Schwann cell scores highlight a very small, distinct cluster, also in the bottom-left, matching the dark blue 'Schwann cell' cluster.
• T cell, B cell, and Mast cell scores show relatively sparse but localized enrichments in specific, small regions, primarily within or adjacent to immune cell clusters or the 'unassigned' population visible in the celltype_major plot. While not explicitly colored in the celltype_major legend, their distinct scores suggest the presence of these immune subtypes.

Progenitor Cells:

• Pancreatic progenitor cell scores are observed in a small, distinct region, often near Ductal cell clusters, which is biologically plausible for progenitor populations. This population might be categorized within 'Stromal cell' or 'unassigned' in the coarser celltype_major annotation.

• Consistency with celltype_major Annotation: The individual HiCAT_major_score plots generally show high consistency with the celltype_major annotations. Regions with high scores for a particular cell type correspond directly to the discrete clusters labeled with that cell type, confirming the robustness of the cell type assignments.

Biological Interpretation

The UMAP visualizations of cell type scores provide strong evidence for the successful classification and spatial segregation of diverse cell populations within the human pancreas.

• Pancreatic Exocrine and Endocrine Compartmentalization: The clear separation of Acinar cells (exocrine) from the various islet cell types (endocrine) and Ductal cells (ductal system) reflects the known anatomical and functional organization of the pancreas. The distinct clusters for Alpha, Beta, Delta, Gamma, and Epsilon cells within the islet cluster underscore the cellular heterogeneity of the islets of Langerhans, crucial for precise glucose homeostasis.
• Microenvironmental Complexity: The presence and distinct clustering of Stromal, Endothelial, Myeloid, T, B, Mast, and Schwann cells highlight the complex microenvironment of the pancreas. Immune cells (Myeloid, T, B, Mast) are key players in inflammatory responses and disease progression, particularly in conditions like Type 2 Diabetes and Prediabetes. Stromal cells, including fibroblasts and endothelial cells, form the structural and vascular support, influencing pancreatic function and disease.
• Annotation Quality: The high degree of overlap between the continuous HiCAT_major_score enrichments and the discrete celltype_major labels validates the quality and accuracy of the cell type annotations. This indicates that the chosen marker genes or gene expression profiles used to generate the scores are reliable discriminators for these cell types.

Annotation Notes

• The HiCAT_major_score plots confirm well-defined and spatially distinct clusters for most major pancreatic cell types, supporting the quality of the celltype_major annotations provided in the AnnData object.
• The presence of distinct score enrichments for T cells, B cells, Mast cells, and Pancreatic progenitor cells, which are not explicitly listed in the celltype_major legend, suggests that these populations might be present as rarer subtypes, potentially subsumed under broader categories like "Myeloid cell", "Stromal cell", or "unassigned" in the primary celltype_major column. Further detailed sub-clustering or minor cell type annotation would be required to explicitly label these populations.
• The unassigned cluster in the celltype_major plot represents cells that do not strongly align with any defined major cell type, and these cells could include rare populations, doublets, or cells in intermediate states.

3. Marker Expression and Annotation Quality Assessment for Pancreatic Cell Subsets

[Analysis Visualization Results]...

Analysis Overview

This analysis employs a marker expression dot plot to visualize the expression levels and detection frequency of selected marker genes across various celltype_subset populations within the Pancreas single-cell RNA-seq dataset. The primary objective is to critically assess and validate the quality and distinctiveness of the assigned celltype_subset annotations by examining their unique gene expression profiles. This serves as a crucial identity check, ensuring the robustness of subsequent downstream analyses in the context of Type 2 Diabetes and Prediabetes.

Visual Summary

The dot plot clearly delineates the specific expression patterns of key marker genes across 13 distinct celltype_subset populations. Each row represents a cell subset, and each column corresponds to a specific gene. The size of each dot reflects the fraction of cells within a group expressing the gene, while the color intensity indicates the mean expression level within that group.

• Distinct Cell Type Signatures: The plot reveals strong, cell-type-specific gene expression patterns, largely concentrated along the diagonal, confirming the unique identities of most annotated cell subsets. These patterns are visually highlighted by red boxes, emphasizing genes with high mean expression (dark red) and high detection frequency (large dots) primarily within their respective cell types.
  • Acinar cells are robustly marked by pancreatic enzyme-related genes such as REG1A, PRSS2, SPINK1, PRSS1, CTRB2, CELA3A, CPA1, and CLPS.
  • Alpha cells exhibit high and specific expression of GCG (Glucagon), CHGA, and TTR.
  • Beta cells are clearly identified by the strong expression of INS (Insulin), IAPP (Amylin), and prohormone convertase PCSK1.
  • Delta cells show characteristic expression of SST (Somatostatin) and GHRL (Ghrelin).
  • Ductal cells are distinguished by epithelial markers like KRT19, KRT7, ANXA4, TACSTD2, MMP7, and SPP1.
  • Endothelial tip cells display specific expression of ESM1 and ANGPT2.
  • Epsilon cells are primarily marked by GHRL.
  • Gamma (PP) cells show strong expression of PPY (Pancreatic Polypeptide).
  • Macrophage (M1) cells are uniquely characterized by chemokine expression, notably CCL3A1 and CCL4A1. The Macrophage (M2B) and Macrophage (M2C) subsets, while sharing some common macrophage markers, also show distinct patterns, with genes like MSR1, SOCS3, STAT1, and NGFR being enriched in some M2 subtypes, suggesting successful discrimination of macrophage polarization states.
  • Schwann cells are identified by S100A10 and FXYD5.
  • Stellate cells exhibit high expression of extracellular matrix components and related genes such as COL1A1, COL1A2, COL6A1, COL6A2, PDGFRB, and SPARC.
• Minimal Cross-Expression: For most major pancreatic cell types, the identified markers show very low or absent expression in other cell populations, indicating high specificity and limited transcriptional overlap between these distinct cellular identities.
• Potential Marker Overlap: A few instances of marker gene expression across multiple cell types are noted, such as GHRL being expressed in both Delta and Epsilon cells, or SPINK1 showing expression in Acinar and Gamma (PP) cells. These instances may reflect shared biological processes, developmental relationships, or the need for combinatorial marker sets for absolute distinction.

Biological Interpretation

The observed marker gene expression profiles robustly support the existing celltype_subset annotations and align well with established biological knowledge of pancreatic cell types.

• Pancreatic Exocrine Cells: The strong expression of digestive enzymes and their regulatory proteins (e.g., REG1A, PRSS1, PRSS2, CTRB2) in Acinar cells unequivocally confirms their identity as the primary producers of digestive enzymes in the pancreas [1].
• Pancreatic Endocrine Cells (Islets of Langerhans): The distinct expression of key hormones and associated processing machinery in the various islet cell types validates their roles in glucose homeostasis and endocrine signaling:

Alpha cells (glucagon-producing, GCG)

Beta cells (insulin-producing, INS, IAPP)

Delta cells (somatostatin-producing, SST)

Gamma (PP) cells (pancreatic polypeptide-producing, PPY)

• Epsilon cells (ghrelin-producing, GHRL) [2].

The co-expression of GHRL in Delta and Epsilon cells may point to shared functions or developmental plasticity within islet cell lineages, consistent with some literature.

• Ductal cells are confirmed by their characteristic cytokeratin expression (KRT19, KRT7), consistent with their epithelial lineage and their role in forming the pancreatic ductal network [3].

Mesenchymal and Immune Cells:

• Pancreatic Stellate cells show high expression of genes related to extracellular matrix remodeling (COL1A1, COL1A2, PDGFRB), which is consistent with their known role in maintaining tissue architecture and their pathogenic activation in fibrosis [4].
• Macrophage subsets (M1, M2B, M2C) exhibit distinct marker profiles that reflect different states of immune polarization and functional specialization within the pancreatic microenvironment. This heterogeneity is critical for understanding immune responses in health and disease, including diabetes [5].
• Endothelial tip cells are marked by genes like ESM1 and ANGPT2, indicating their specific function in angiogenesis and vascular development within the pancreas [6].
• Schwann cells are appropriately identified by markers such as S100A10, reflecting their role in supporting neural structures within the organ [7].

Annotation Notes

The marker expression dot plot provides robust evidence that the celltype_subset annotations within this AnnData object are well-supported and represent distinct, biologically meaningful cell populations in the Pancreas.

• High Confidence in Cell Identities: The clear and specific expression of established marker genes for the majority of celltype_subset annotations validates their assignment. The distinct "diagonal" pattern of enriched markers strongly confirms the quality of the cell clustering and annotation process.
• Resolution of Subtypes: The analysis successfully distinguishes between various macrophage subsets and different endocrine cell types, demonstrating the ability of these annotations to capture crucial cellular heterogeneity relevant to pancreatic biology and disease.
• Foundation for Downstream Analysis: The strong validation of cell type identities through this marker expression analysis provides a high level of confidence for proceeding with more in-depth investigations, such as differential gene expression analysis, pathway enrichment, and cell-cell interaction studies, particularly in the context of Type 2 Diabetes and Prediabetes. This precise cell typing is foundational for interpreting disease-associated changes.

---

References:

[1] Acinar cell function: PubMed search for "pancreatic acinar cell function digestive enzymes" [PubMed Search]

[2] Islet cell hormones: GeneCards for GCG (Glucagon) [GeneCards], INS (Insulin) [GeneCards], SST (Somatostatin) [GeneCards], PPY (Pancreatic Polypeptide) [GeneCards], GHRL (Ghrelin) [GeneCards]

[3] Ductal cell markers and function: PubMed search for "pancreatic ductal cell KRT19 KRT7" [PubMed Search]

[4] Pancreatic stellate cells: PubMed search for "pancreatic stellate cell collagen PDGFRB" [PubMed Search]

[5] Macrophage polarization in pancreas/diabetes: PubMed search for "pancreatic macrophage polarization diabetes" [PubMed Search]

[6] Endothelial tip cells: PubMed search for "endothelial tip cell ESM1 ANGPT2" [PubMed Search]

[7] Schwann cell markers: GeneCards for S100A10 [GeneCards]

4. Pancreatic Minor Cell Type Population Dynamics Across Diabetic Conditions

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a stacked bar plot visualizing the relative proportions of minor cell types within individual pancreatic samples. The samples are grouped by their disease condition: non_diabetic, prediabetes, and type2_diabetes. Each bar represents a unique sample, with segments colored to denote the fractional abundance of distinct minor cell populations identified from single-cell RNA-seq data. The primary objective is to discern any significant shifts or characteristic patterns in the cellular composition of the pancreas in relation to the progression of Type 2 Diabetes.

Visual Summary

• The visualization comprises three panels, one for each condition (non_diabetic, prediabetes, type2_diabetes), showing a total of 30 individual samples (14 non_diabetic, 8 prediabetes, 8 type2_diabetes).
• Acinar cells (burgundy) and Alpha cells (dark red) consistently represent the largest cell populations across almost all samples and conditions. Their combined proportion frequently exceeds 50% of the total cells.
• Beta cells (red-orange) and Ductal cells (light orange) are also consistently present as substantial populations, often appearing as the third and fourth most abundant cell types. Delta cells (orange) are present in smaller, yet consistent, proportions.
• Other minor cell types, including Endothelial cells, Epsilon cells, Fibroblasts, Gamma (PP) cells, Macrophages, Schwann cells, Smooth muscle cells, and Stellate cells, generally constitute very low proportions, often being visually minimal within the bars.
• A notable observation is the "unassigned" cell population (dark blue). Its proportion varies considerably from sample to sample, ranging from negligible to over 20% in certain individual samples, without a clear trend related to the disease condition.
• Overall, there is considerable sample-to-sample variability in the distribution of cell type proportions within each condition. This inherent heterogeneity makes it challenging to identify a consistent, widespread shift in the proportions of major pancreatic cell types (Acinar, Alpha, Beta, Ductal) across the disease progression from non_diabetic to prediabetes to type2_diabetes based solely on this visual assessment.

Biological Interpretation

The pancreas plays a pivotal role in glucose homeostasis, and its cellular composition is profoundly impacted in metabolic disorders like Type 2 Diabetes (T2D).

• Dominant Pancreatic Cell Types: The high and consistent abundance of Acinar cells (exocrine pancreas) and Alpha cells (endocrine pancreas, glucagon-producing) is expected. These cell types form the structural and functional core of the pancreas, respectively.
• Beta Cell Proportions and Diabetes: Beta cells are crucial for insulin production, and their dysfunction or loss is a hallmark of T2D. While the plot shows Beta cells as a significant population, a universally consistent decline in their *relative proportion* across all type2_diabetes samples compared to non_diabetic controls is not overtly discernible. This observation could reflect:
  • Heterogeneity of T2D: Beta cell mass changes are highly variable in T2D, influenced by disease duration, severity, and individual factors PubMed search: beta cell mass type 2 diabetes heterogeneity.
  • Relative vs. Absolute Counts: This plot shows relative proportions. An absolute decrease in beta cell numbers might occur without a proportional shift if other cell types also decrease or remain stable.
  • Function vs. Quantity: This analysis primarily addresses cell quantity, not their functional state. Beta cells in T2D are often characterized by severe dysfunction even before significant numerical loss GeneCards: INS gene.
• Ductal Cell Stability: Ductal cells are involved in pancreatic development and possess regenerative potential, potentially contributing to islet repair or neogenesis PubMed search: pancreatic ductal cells regeneration diabetes. Their relatively stable proportions across conditions suggest their continued structural presence.
• Minor Stromal and Immune Components: The generally low proportions of stromal cells (e.g., Fibroblasts, Stellate cells) and immune cells (e.g., Macrophages) are typical. Significant increases in these populations would usually indicate inflammation, fibrosis, or tissue remodeling processes, which are known to occur in the diabetic pancreas but might not manifest as large-scale proportional changes in an overall tissue analysis or might be highly localized PubMed search: pancreatic inflammation fibrosis diabetes.
• Implications of "Unassigned" Cells: The variable and sometimes substantial fraction of "unassigned" cells suggests potential areas for further investigation. These could represent cells that are technically challenging to classify, or they might indicate novel cell states or transitional populations that are not adequately captured by the existing minor cell type annotations. Such uncharacterized populations, particularly if enriched in disease conditions, could offer insights into disease pathology.

Annotation Notes

• The considerable sample-to-sample variability observed across all conditions underscores the biological diversity in human pancreatic tissue and the heterogeneous nature of prediabetes and type2_diabetes pathogenesis. This variability highlights the importance of analyzing changes at a finer resolution (e.g., specific markers, gene expression changes) rather than relying solely on broad population shifts from this type of plot.
• The "unassigned" category is an important aspect of this dataset. Further analysis of the gene expression profiles of these unassigned cells could be valuable. This might lead to the identification of new cell populations, refined existing annotations, or insights into technical challenges in specific samples that could impact downstream analyses.

5. Pancreatic Macrophage Subset Composition Across Diabetes Progression

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates the relative proportions of different macrophage subsets (M1, M2A, M2B, M2C, M2D) within the pancreatic tissue across three conditions: non_diabetic, prediabetes, and type2_diabetes. The results are presented as stacked bar plots, with each bar representing a single sample and showing the percentage composition of macrophage subsets. This provides insight into how the macrophage immune landscape within the pancreas changes with the progression of diabetes.

Visual Summary

The stacked bar plots illustrate the population distribution of macrophage subsets (Macrophage (M1), Macrophage (M2A), Macrophage (M2B), Macrophage (M2C), Macrophage (M2D)) for individual samples across non_diabetic, prediabetes, and type2_diabetes conditions.

1. Macrophage (M1) Dominance: Macrophage (M1) (dark red) consistently represents the largest proportion of macrophages in the pancreas across all conditions.
2. Increasing M1 Proportion in Diabetes: There is a discernible trend of increasing relative abundance of Macrophage (M1) from non_diabetic to prediabetes, and further into type2_diabetes. In many type2_diabetes samples, Macrophage (M1) constitutes over 70-80% of the total macrophage population.
3. Decreasing M2C and M2D in Diabetes: Conversely, the proportions of Macrophage (M2C) (light yellow) and Macrophage (M2D) (teal) appear to decrease with disease progression. Macrophage (M2C) is relatively abundant in non_diabetic samples but shows a reduction in prediabetes and is further diminished in type2_diabetes. Macrophage (M2D) is present in several non_diabetic samples but becomes rare or almost absent in the prediabetes and type2_diabetes groups.
4. Stable M2A and M2B: Macrophage (M2A) (orange) and Macrophage (M2B) (light orange) generally remain minor components of the macrophage population across all conditions, without a clear directional trend of significant change.

Biological Interpretation

The observed shifts in pancreatic macrophage populations suggest a critical role for immune cell polarization in the pathogenesis of Type 2 Diabetes.

• M1 Macrophages and Pro-inflammatory State: Macrophage (M1) subsets are traditionally associated with a pro-inflammatory phenotype, characterized by the production of pro-inflammatory cytokines and involvement in immune activation and tissue damage. The progressive increase in Macrophage (M1) populations from non_diabetic to type2_diabetes suggests a sustained and escalating inflammatory environment within the pancreas as diabetes develops. Chronic inflammation in the pancreas is known to contribute to beta cell dysfunction and death, crucial events in T2D.
• M2 Macrophages and Anti-inflammatory/Regulatory Roles: Macrophage (M2) subsets (including M2A, M2B, M2C, M2D) are generally involved in anti-inflammatory responses, tissue remodeling, immune regulation, and repair. The reduction in Macrophage (M2C) and particularly Macrophage (M2D) in prediabetes and type2_diabetes implies a diminished capacity for resolving inflammation or maintaining tissue homeostasis. Macrophage (M2D), for instance, has been implicated in immune suppression and could play a role in maintaining immune tolerance. Its reduction could signify a loss of regulatory control.
• Imbalance in Macrophage Polarization: The overall picture points to an imbalance in macrophage polarization, shifting from a potentially more balanced or M2-inclusive state in non-diabetic individuals towards a predominantly M1-driven, pro-inflammatory state in diabetic conditions. This shift contributes to the chronic low-grade inflammation characteristic of T2D, impacting insulin sensitivity and beta cell function.

Clinical or Translational Implications

The changes in macrophage subset composition observed here have significant clinical implications for understanding and potentially managing Type 2 Diabetes:

• Biomarker Potential: The increased proportion of Macrophage (M1) and decreased proportions of Macrophage (M2C) and Macrophage (M2D) could serve as potential biomarkers for assessing disease progression or risk in pancreatic tissue.
• Therapeutic Targets: Targeting macrophage polarization represents a promising therapeutic strategy. Interventions aimed at dampening M1 activation or promoting M2-like phenotypes, especially M2C and M2D, could potentially mitigate pancreatic inflammation, improve beta cell function, and slow down or halt disease progression in individuals with prediabetes or early-stage T2D.
• Understanding Pathogenesis: These findings reinforce the role of immune dysregulation and chronic inflammation in T2D pathogenesis, highlighting the pancreas as a site of active immune cell remodeling during disease development. This understanding is critical for developing new treatments beyond traditional metabolic approaches.

6. Cell-Cell Interaction Patterns in Human Pancreas Across Diabetes Conditions

[Analysis Visualization Results]...

Analysis Overview

This analysis utilizes single-cell RNA-seq data from human pancreatic tissue to explore cell-cell interaction (CCI) patterns across different metabolic states: non-diabetic, prediabetes, and type 2 diabetes. Using the CellPhoneDB algorithm, ligand-receptor interactions between various pancreatic cell types (celltype_minor) have been identified and visualized. The plots display the top 80 most significant interactions for each condition, with dot size and color intensity representing the log2(mean) expression of the ligand-receptor pair (interaction strength) and the border color/thickness representing the -log10(p-value) (statistical significance). This allows for a comparative assessment of intercellular communication dynamics in pancreatic health and disease progression.

Visual Summary

The three dot plots provide a comparative overview of significant cell-cell interactions in the pancreas for non-diabetic, prediabetic, and type 2 diabetic conditions.

• Dominance of Integrin-Mediated Interactions: A striking feature across all three conditions is the high prevalence and strong signal of integrin-mediated interactions. These include various collagen (e.g., COL1A1_integrin_a1b1_complex, COL4A1_integrin_a2b1_complex), fibronectin (FN1_integrin_a5b1_complex, FN1_integrin_avb3_complex), and laminin (LAMC1_integrin_a2b1_complex) ligand-receptor pairs. These interactions involve a wide array of cell types, including Alpha, Beta, Delta, Ductal, Acinar, and particularly Stellate cells, indicating their crucial role in extracellular matrix (ECM) organization and cell adhesion within the pancreatic microenvironment.
• Persistent Inflammatory/Fibrotic Signaling: Interactions involving SPP1 (Osteopontin) with various integrin complexes (e.g., SPP1_integrin_avb5) and TGFBI (TGF-beta induced) with TGFB_receptor1/2 are consistently observed and often show strong signals (indicated by bright green/yellow dots) across all conditions. These interactions frequently involve Stellate cells, Alpha cells, and Delta cells, suggesting active roles for these pathways in pancreatic inflammation and fibrosis regardless of diabetes status, albeit with potential modulations in strength.
• Condition-Specific Intensification of LCN2-SLC2A1 Axis: A notable trend with disease progression is the apparent intensification of LCN2_SLC2A1 (Lipocalin-2 - GLUT1) interactions. For example, Delta|Ductal and Beta|Ductal cell-cell interactions involving LCN2_SLC2A1 appear to show an increase in log2(mean) expression (shifting from lighter green to brighter green/yellow) from non-diabetic to prediabetic and then to type 2 diabetic conditions. This suggests an upregulation of this specific intercellular communication axis during diabetes progression.
• WNT and NOTCH Signaling: Interactions related to WNT signaling (e.g., WNT2B-FZD5, WNT4-LRP5/6_complex) and NOTCH signaling (e.g., DLK1_NOTCH1/2) are also present, primarily involving islet cells (Alpha, Beta, Delta) and Ductal cells. While generally present across conditions, their precise contribution to disease progression would require detailed quantitative comparison beyond visual inspection of the top 80 interactions.

Biological Interpretation

The analysis highlights critical cell-cell communication networks in the human pancreas and their alterations in the context of Type 2 Diabetes and Prediabetes.

• ECM Remodeling and Fibrosis: The pervasive nature of integrin-mediated interactions with ECM components (collagens, fibronectin, laminins) underscores the importance of the ECM in maintaining pancreatic architecture and function. Pancreatic fibrosis, characterized by excessive ECM deposition and remodeling, is a known feature of diabetes progression. The consistent presence of these interactions, particularly involving Stellate cells (known for their fibrogenic potential), suggests ongoing ECM dynamics, which may become dysregulated in diabetic conditions.
  • SPP1-integrin and TGFBI-TGFBR Signaling: The robust signaling through SPP1-integrin and TGFBI-TGFBR pathways is highly relevant. SPP1 (osteopontin) is a cytokine that promotes inflammation, cell migration, and fibrosis, often elevated in diabetic complications. TGF-beta signaling is a central mediator of fibrosis and cellular plasticity. Their strong and consistent presence, especially involving Alpha, Delta, and Stellate cells, indicates active inflammatory and fibrotic processes within the islets and surrounding tissue, which are exacerbated in diabetes [1].
• LCN2-SLC2A1 Axis in Metabolic Dysfunction: The observed increase in LCN2_SLC2A1 interactions in prediabetes and type 2 diabetes, particularly between Beta/Delta cells and Ductal cells, is a significant finding. LCN2 (Lipocalin-2) is an adipokine and inflammatory protein linked to insulin resistance, β-cell dysfunction, and systemic inflammation in obesity and diabetes [2]. SLC2A1 (GLUT1) is a glucose transporter. Increased LCN2_SLC2A1 interaction could indicate enhanced communication linking inflammatory stress with altered glucose metabolism, potentially impacting insulin secretion or β-cell survival. Ductal cells play roles in islet regeneration and ductal adenocarcinomas, and communication with islet cells is crucial.
• Islet Homeostasis and Cell Fate: The presence of WNT and NOTCH signaling interactions suggests their continued role in maintaining islet cell identity, proliferation, and differentiation. Dysregulation of these pathways can contribute to β-cell mass changes and dysfunction in diabetes [3].

Clinical or Translational Implications

The identified cell-cell interaction patterns offer potential avenues for therapeutic intervention and biomarker discovery in Type 2 Diabetes.

• Therapeutic Targeting of Inflammatory/Fibrotic Pathways: The consistently strong SPP1-integrin and TGFBI-TGFBR interactions suggest that modulating these pathways, particularly those involving pancreatic stellate cells, could be a strategy to attenuate pancreatic inflammation and fibrosis in diabetes. Specific receptor antagonists or signaling inhibitors could be explored.
• Modulating the LCN2-SLC2A1 Axis: The apparent upregulation of LCN2_SLC2A1 interactions in diabetic conditions presents a novel target. Therapeutic strategies aimed at blocking LCN2 or its interaction with GLUT1, specifically between islet cells and ductal cells, could potentially mitigate aspects of β-cell dysfunction, insulin resistance, or inflammatory responses in the pancreas.
• Biomarker Potential: Changes in the expression levels of key ligands (e.g., LCN2, SPP1) or receptors (e.g., integrin subunits, GLUT1) within specific pancreatic cell types, or their presence in circulation, could serve as novel biomarkers for monitoring disease progression from prediabetes to type 2 diabetes, or for assessing response to anti-diabetic therapies.
• Experimental Validation: Future studies should focus on validating these interactions experimentally. This could involve *in vitro* co-culture experiments using isolated pancreatic cell types to confirm the functionality of predicted ligand-receptor pairs, assessing their impact on cell function (e.g., insulin secretion, proliferation, fibrotic marker expression), and *in vivo* studies using genetic or pharmacological interventions in diabetes animal models to determine the therapeutic potential of targeting these specific CCI pathways.

References

[1] The role of pancreatic stellate cells in pancreatic fibrosis. PubMed search: https://pubmed.ncbi.nlm.nih.gov/?term=pancreatic+stellate+cells+fibrosis+diabetes

[2] Lipocalin-2 (LCN2) and diabetes. GeneCards LCN2: https://www.genecards.org/cgi-bin/carddisp.pl?gene=LCN2

[3] Wnt signaling in pancreatic beta-cell development and diabetes. PubMed search: https://pubmed.ncbi.nlm.nih.gov/?term=Wnt+signaling+pancreatic+beta+cell+diabetes

7. Condition-Specific Cell-Cell Interaction Patterns in Pancreatic Cells Across Diabetic States

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates condition-specific cell-cell interaction (CCI) patterns within pancreatic tissues from individuals categorized as non-diabetic, prediabetic, and type 2 diabetic. Utilizing single-cell RNA sequencing data and CellPhoneDB, a dot plot visualization was generated to highlight significant ligand-receptor interactions across various cell types, including major tissue cells, immune cells, and stromal cells. The plot visualizes the interaction strength (color intensity, 'Scaled log strength') and statistical significance (dot size, -log10(p-value)) for the top 60 significant interactions per condition across individual samples. The primary goal is to identify how cell communication networks are altered in prediabetes and type 2 diabetes compared to a non-diabetic state.

Visual Summary

The dot plot reveals distinct patterns of cell-cell interactions across the three conditions: non-diabetic, prediabetes, and type2_diabetes.

• Non-diabetic Condition: A prominent block of strong and statistically significant interactions (dark red, large dots) is observed in many non-diabetic samples (e.g., MS19001, MS19003, MS19004, MS19018, MS19022, MS19032). These interactions span various cell-cell pairs and molecular pathways, indicating a robust and active intercellular communication network. Specific examples include strong WNT, Integrin, and other signaling pathways active in these samples.
• Prediabetes Condition: Compared to the non-diabetic group, many of the highly active interactions observed in non-diabetic samples appear attenuated or less prevalent in prediabetic samples. While some interactions remain active, there is a general reduction in the overall strength and number of significant interactions for certain sample clusters (e.g., MS19001-MS19038 samples show fewer strong interactions). Conversely, a few distinct interactions emerge or become stronger in other prediabetic samples.
• Type 2 Diabetes Condition: The type 2 diabetes group displays a unique and highly active interaction signature. A particularly striking pattern is observed in a cluster of samples (e.g., MS17001, MS17003, MS17004, MS17005), which show relatively weak activity in non-diabetic and prediabetic states but exhibit a strong and widespread activation of numerous interactions in type 2 diabetes. This cluster primarily involves Bone Morphogenetic Protein (BMP) signaling and Desmosterol-related interactions among Beta, Ductal, and Delta cells. Other type 2 diabetic samples also show specific patterns of activated CCIs, some overlapping with non-diabetic and some unique.

Overall, the visualization suggests a dynamic remodeling of the pancreatic cellular communication landscape from health to prediabetes and full-blown type 2 diabetes, with distinct sets of interactions being modulated at different disease stages.

Biological Interpretation

The observed condition-specific CCI patterns provide insight into the molecular mechanisms underlying diabetes progression.

1. Maintenance of Pancreatic Homeostasis in Non-diabetic State:
   • Interactions like WNT4_FZD1_LRP6 -- Beta | Ductal are prominent in non-diabetic samples. The WNT/β-catenin pathway is critical for pancreatic development, maintenance of beta-cell mass, and regulation of beta-cell function. Optimal WNT signaling is essential for the proliferation, survival, and differentiation of pancreatic cells [1]. Its strong presence in non-diabetic samples suggests its role in maintaining healthy islet and ductal cell crosstalk.
   • COL1A1_integrin_a11b1_complex -- Stellate | Stellate indicates active collagen-integrin interactions among pancreatic stellate cells. These interactions are crucial for maintaining the extracellular matrix (ECM) and normal tissue architecture, reflecting healthy stromal cell function in the absence of disease GeneCards: COL1A1.
2. Dysregulation and Shifts in Prediabetes:
   • The general attenuation of some key interactions in prediabetes may reflect early signs of pancreatic stress or dysfunction. A decrease in crucial signaling for beta-cell health could contribute to impaired glucose homeostasis. This stage might involve an adaptive response or the initiation of detrimental changes in cell communication, contributing to the progressive decline in pancreatic function.
3. Emergence of Pro-Diabetic Signaling in Type 2 Diabetes:
   • A striking feature in type 2 diabetic samples is the strong activation of BMP5_ACVR1_BMPR2 interactions across Beta, Ductal, and Delta cells. Bone Morphogenetic Proteins (BMPs) are part of the TGF-beta superfamily, regulating cell proliferation, differentiation, and apoptosis. While some BMPs support beta-cell function, others can induce apoptosis or impair insulin secretion. Dysregulated BMP signaling has been implicated in the pathogenesis of diabetes by affecting islet architecture and function [2]. The high activity suggests an altered signaling environment that may contribute to beta-cell dysfunction or maladaptive plasticity.
   • Furthermore, Desmosterol_byDHCR7_NR1H2 interactions are highly active in type 2 diabetic samples, particularly among Beta, Ductal, and Delta cells. Desmosterol is an intermediate in cholesterol biosynthesis, and NR1H2 encodes Liver X Receptor beta (LXRB), a nuclear receptor that plays a key role in lipid and glucose metabolism. LXRs respond to oxysterols like desmosterol to regulate genes involved in cholesterol efflux, fatty acid synthesis, and inflammation. Upregulation of these interactions might indicate altered lipid metabolism within islet cells, which can contribute to lipotoxicity, inflammation, and insulin resistance, central to T2D pathology GeneCards: NR1H2.

Clinical or Translational Implications

The identification of condition-specific CCI patterns offers potential avenues for therapeutic intervention in diabetes.

• Targeting Dysregulated BMP Signaling: The strong upregulation of BMP5-receptor interactions in type 2 diabetes suggests that modulating this pathway could be a therapeutic strategy. Selective inhibitors of specific BMP receptors or downstream signaling molecules could potentially mitigate adverse effects on beta-cell function or ductal cell plasticity, aiming to restore a healthier pancreatic microenvironment. However, BMP signaling is complex, and care must be taken to avoid off-target effects.
• Modulating LXR Activity via Desmosterol: The increased activity of Desmosterol-NR1H2 interactions in type 2 diabetes points to altered lipid signaling as a driver of disease. Pharmacological modulation of LXRB activity, perhaps with selective agonists or antagonists, could be explored to improve lipid homeostasis, reduce lipotoxicity in islet cells, and enhance insulin sensitivity. While pan-LXR agonists have shown metabolic benefits, challenges such as inducing hepatic steatosis need to be addressed, potentially through tissue-specific targeting or partial agonists [3].
• Restoring WNT Signaling in Prediabetes: Given the potential attenuation of beneficial WNT signaling in prediabetes, therapeutic strategies aimed at restoring or enhancing specific WNT pathways could be investigated. This might involve WNT agonists to promote beta-cell proliferation and survival, potentially halting or reversing disease progression at an earlier stage.
• Addressing ECM Remodeling: Changes in integrin-mediated interactions, even if subtle, warrant further investigation as ECM remodeling is a hallmark of diabetic complications like fibrosis. Targeting specific integrins involved in pathological pancreatic fibrosis, particularly those interacting with pancreatic stellate cells or fibroblasts, could improve islet function and prevent further tissue damage.

Further experimental validation is necessary to confirm the functional significance of these identified interactions and their potential as therapeutic targets.

---

References:

1. WNT signaling in pancreatic beta cells: PubMed search: WNT signaling beta cell diabetes
2. BMP signaling in diabetes: PubMed search: BMP signaling pancreas diabetes
3. LXR in metabolic diseases: PubMed search: LXR diabetes treatment

8. Beta Cell Condition-Specific Surfaceome Marker Analysis in Type 2 Diabetes

[Analysis Visualization Results]...

Analysis Overview

This analysis identifies and visualizes surfaceome markers specifically expressed in pancreatic Beta cells from individuals with Type 2 Diabetes compared to non-diabetic controls. The dot plot displays the mean expression level (color intensity) and the fraction of cells expressing each marker (dot size) across individual samples, grouped by condition (non_diabetic and type2_diabetes). The markers were selected based on differential expression analysis against the non_diabetic reference condition, focusing on surfaceome-localized genes with significant changes in expression and prevalence. This provides insight into changes in Beta cell surface proteins that may mediate cell-cell interactions, signaling, and overall function in the context of Type 2 Diabetes.

Visual Summary

The dot plot visualizes the expression patterns of 10 selected Beta cell surfaceome markers across 44 individual samples from non-diabetic and type 2 diabetic donors.

• Overall Pattern: Markers are broadly grouped into two categories: those predominantly expressed in non-diabetic Beta cells (CD68, FFAR4, SERINC2, BACE1) and those predominantly expressed in Type 2 Diabetic Beta cells (LSAMP, TM4SF4, EFNA5, TSPAN5, PLXNA2, LDLR).

Markers Enriched in Non-diabetic Beta Cells

• CD68, FFAR4, SERINC2, BACE1: These markers show consistently darker red coloration and larger dot sizes within the 'non_diabetic' samples, indicating higher mean expression and a greater fraction of expressing Beta cells compared to 'type2_diabetes' samples. This suggests a potential downregulation of these markers in Type 2 Diabetes.

Markers Enriched in Type 2 Diabetic Beta Cells

• LSAMP, TM4SF4, EFNA5, TSPAN5, PLXNA2, LDLR: Conversely, these markers exhibit darker red coloration and larger dot sizes in 'type2_diabetes' samples, pointing to increased expression and/or prevalence in diabetic Beta cells compared to non-diabetic controls.

• Sample Variability: Within each condition, there is notable variability in marker expression and prevalence across individual samples, indicating heterogeneity in Beta cell responses among donors.
• Cell Count per Sample: The bar chart on the right indicates the number of Beta cells analyzed per sample, ranging from approximately 241 (MS19038) to 1394 (MS21003), confirming sufficient cell numbers for robust analysis in most samples.

Biological Interpretation

The observed differential expression of these surfaceome markers in Beta cells highlights specific molecular changes occurring in the pancreatic islets during Type 2 Diabetes.

Markers with Higher Expression in Non-diabetic Beta Cells:

1. CD68:
   • Signaling Pathways & Mechanisms: While primarily a macrophage marker, its expression in Beta cells, especially in a non-diabetic context, could indicate a basal level of cellular turnover, stress response, or lysosomal activity. CD68 is associated with lysosomal membranes and functions in phagocytosis and antigen presentation. In non-diabetic Beta cells, this might reflect healthy cellular housekeeping, while its downregulation in T2D could suggest impaired clearance mechanisms or altered stress responses. GeneCards: CD68
   • Therapeutic Potential: If a certain level of CD68 expression or its associated functions are protective in healthy Beta cells, understanding the consequences of its reduction in T2D is crucial. Direct therapeutic targeting of Beta cell CD68 is not common, but interventions that support healthy lysosomal function or cellular waste management might be relevant.
2. FFAR4 (Free Fatty Acid Receptor 4):
   • Signaling Pathways & Mechanisms: FFAR4 is a G protein-coupled receptor (GPCR) that senses long-chain fatty acids. In Beta cells, its activation can lead to enhanced glucose-stimulated insulin secretion (GSIS) and Beta cell proliferation and survival. It often signals through Gq/11 proteins to activate PLC and raise intracellular Ca2+, or through beta-arrestin pathways, mediating anti-inflammatory effects. Its higher expression in non-diabetic Beta cells suggests a healthy capacity to respond to circulating lipids, promoting proper insulin secretion and potentially protecting against lipotoxicity. Reduced FFAR4 in T2D could contribute to impaired insulin secretion and increased inflammation. GeneCards: FFAR4
   • Therapeutic Potential: FFAR4 agonists have been investigated as potential therapeutic agents for Type 2 Diabetes due to their insulin-sensitizing and anti-inflammatory properties. Restoring FFAR4 expression or activating its signaling in diabetic Beta cells could improve Beta cell function and survival, potentially mitigating disease progression.
3. SERINC2 (Serine Incorporator 2):
   • Signaling Pathways & Mechanisms: SERINC2 is a multi-pass transmembrane protein involved in the incorporation of serine into membrane lipids, primarily phosphatidylserine. It plays a role in lipid metabolism and membrane biosynthesis. While its direct function in Beta cells in diabetes is less characterized, alterations in lipid metabolism are central to T2D pathogenesis and Beta cell lipotoxicity. Higher SERINC2 in non-diabetic cells may reflect healthy lipid homeostasis. GeneCards: SERINC2
   • Therapeutic Potential: Given its role in lipid metabolism, SERINC2 could represent an indirect target. Modulating lipid synthesis pathways that involve SERINC2 might alleviate lipotoxicity in diabetic Beta cells, although specific therapeutic agents are not currently established for this target in diabetes.
4. BACE1 (Beta-site APP-Cleaving Enzyme 1):
   • Signaling Pathways & Mechanisms: BACE1, known for its role in Alzheimer's disease, is also expressed in pancreatic islets. It is an aspartyl protease that cleaves various transmembrane proteins. In Beta cells, BACE1 has been implicated in processing proteins involved in insulin secretion and islet amyloid polypeptide (IAPP) formation, which contributes to Beta cell dysfunction and death in T2D. Its higher expression in non-diabetic Beta cells suggests a potentially healthy or context-dependent proteolytic activity, which might be critical for specific substrate processing in maintaining Beta cell function. A reduction in BACE1 in T2D could lead to dysregulation of its substrates. GeneCards: BACE1
   • Therapeutic Potential: BACE1 inhibitors have been explored for Alzheimer's disease. In diabetes, modulating BACE1 activity could influence islet amyloidogenesis and insulin secretion. If the observed downregulation in T2D is detrimental, strategies to restore specific BACE1-mediated proteolytic events (not related to amyloid formation) could be explored, though this is complex given its multifaceted roles.

Markers with Higher Expression in Type 2 Diabetic Beta Cells:

1. LSAMP (Limbitin):
   • Signaling Pathways & Mechanisms: LSAMP is a neuronal adhesion molecule involved in nervous system development and axon guidance. Its upregulation in Type 2 Diabetic Beta cells might suggest altered cell-cell adhesion properties within the islet, changes in islet innervation, or a stress-induced response leading to Beta cell dedifferentiation or phenotypic shifts. This could contribute to the remodeling and dysfunction observed in diabetic islets. GeneCards: LSAMP
   • Therapeutic Potential: If LSAMP's increased expression contributes to maladaptive changes in Beta cell adhesion or interactions, targeting it could help stabilize islet architecture or Beta cell function. However, specific therapeutic agents for LSAMP in diabetes are not known.
2. TM4SF4 (Transmembrane 4 L six family member 4):
   • Signaling Pathways & Mechanisms: TM4SF4 belongs to the tetraspanin family, which acts as molecular facilitators on the cell surface, organizing proteins into functional complexes. Tetraspanins influence cell adhesion, migration, proliferation, and signal transduction. Its upregulation in diabetic Beta cells could reflect altered cell surface organization, potentially impacting cell-cell communication, Beta cell survival, or their ability to adapt to metabolic stress, possibly driving dedifferentiation processes. GeneCards: TM4SF4
   • Therapeutic Potential: Modulating tetraspanin function could indirectly impact Beta cell plasticity and survival. Further research is needed to determine if TM4SF4 upregulation in Beta cells is protective, compensatory, or detrimental, to inform therapeutic strategies.
3. EFNA5 (Ephrin A5):
   • Signaling Pathways & Mechanisms: EFNA5 is a ligand for Ephrin receptors, mediating crucial contact-dependent cell-cell communication. Ephrin-Eph signaling is involved in tissue patterning, cell migration, axon guidance, and angiogenesis. In the pancreas, it could regulate islet architecture, Beta cell proliferation, or communication with other islet cell types and endothelial cells. Its upregulation in diabetic Beta cells may indicate altered developmental pathways or maladaptive remodeling of the islet microenvironment, contributing to Beta cell dysfunction or reduced mass. GeneCards: EFNA5
   • Therapeutic Potential: Manipulating Ephrin-Eph signaling pathways holds potential to modulate islet architecture, Beta cell regeneration, or prevent pathological remodeling in diabetes. Specific small molecule inhibitors or agonists targeting EFNA5-Eph interactions could be explored.
4. TSPAN5 (Tetraspanin 5):
   • Signaling Pathways & Mechanisms: Similar to TM4SF4, TSPAN5 is a tetraspanin involved in organizing membrane microdomains and facilitating interactions between various cell surface proteins, including integrins and GPCRs. Its increased expression in T2D Beta cells suggests a broader dysregulation of cell surface dynamics, potentially impacting Beta cell adhesion to the extracellular matrix, nutrient sensing, or inflammatory signaling within the islet, contributing to impaired function. GeneCards: TSPAN5
   • Therapeutic Potential: As with other tetraspanins, TSPAN5 itself might not be a direct drug target, but understanding its role in organizing key signaling complexes could inform strategies to modulate those pathways for therapeutic benefit in diabetes.
5. PLXNA2 (Plexin A2):
   • Signaling Pathways & Mechanisms: PLXNA2 is a receptor for semaphorins, which are guidance cues involved in nervous system development, immune responses, and vascular patterning. In Beta cells, PLXNA2 could mediate interactions with islet innervation, immune cells, or play a role in vascular changes within the islet during T2D. Semaphorin-Plexin signaling can influence cell migration and survival. Its upregulation might signify altered neural input, inflammatory cues, or Beta cell attempts at adaptive (or maladaptive) migration/remodeling. GeneCards: PLXNA2
   • Therapeutic Potential: Modulating PLXNA2 and its semaphorin ligands could represent a strategy to improve islet innervation, dampen neuroinflammation, or influence Beta cell plasticity, but this requires further mechanistic understanding in the context of diabetes.
6. LDLR (Low-Density Lipoprotein Receptor):
   • Signaling Pathways & Mechanisms: LDLR is a crucial cell surface receptor responsible for the uptake of cholesterol-rich LDL particles from circulation. Dysregulated lipid metabolism and lipotoxicity are significant contributors to Beta cell dysfunction and death in Type 2 Diabetes. Upregulation of LDLR in diabetic Beta cells could indicate increased lipid uptake, potentially as a compensatory mechanism to clear excess circulating lipids, or it could exacerbate intracellular lipid accumulation leading to lipotoxicity and Beta cell stress. GeneCards: LDLR
   • Therapeutic Potential: LDLR is a well-established therapeutic target for hypercholesterolemia, with drugs like statins and PCSK9 inhibitors widely used. In the context of Beta cells, if increased LDLR activity leads to lipotoxicity, strategies to carefully modulate LDLR expression or downstream lipid processing within Beta cells could be beneficial. However, LDLR is also critical for cellular health, so any intervention would need to be carefully considered for its specific impact on Beta cells.

Clinical or Translational Implications

The identification of these differentially expressed surfaceome markers provides valuable insights into the molecular pathology of Type 2 Diabetes in pancreatic Beta cells and offers potential avenues for clinical and translational applications:

• Biomarker Discovery: Markers like FFAR4 (downregulated in T2D) and LDLR (upregulated in T2D) could serve as potential biomarkers for Beta cell health or disease progression. While single-cell RNA-seq identifies mRNA levels, verification of protein expression on the cell surface would be critical for true biomarker utility.

Therapeutic Targets

• FFAR4: The reduction of FFAR4 in Type 2 Diabetic Beta cells suggests that preserving or augmenting its activity might be a beneficial therapeutic strategy. FFAR4 agonists, already explored for T2D, could potentially be used to enhance Beta cell insulin secretion and improve survival.
• LDLR: The increased expression of LDLR in Type 2 Diabetic Beta cells points to potential dysregulation of lipid handling. Strategies to mitigate lipotoxicity in Beta cells could involve modulating LDLR activity or associated downstream lipid metabolism pathways. Given that drugs like PCSK9 inhibitors increase hepatic LDLR to lower plasma LDL, the specific impact of such agents on Beta cell LDLR and function would need careful evaluation.
• Adhesion/Signaling Molecules (LSAMP, TM4SF4, EFNA5, TSPAN5, PLXNA2): The altered expression of these cell surface adhesion and signaling molecules suggests a profound remodeling of Beta cell interactions and communication within the islet microenvironment in Type 2 Diabetes. These markers could represent novel targets for interventions aimed at preserving islet architecture, Beta cell integrity, or modulating detrimental cell-cell interactions.

• Disease Mechanisms: These markers offer clues into the underlying biological mechanisms of Type 2 Diabetes, including altered lipid sensing (FFAR4, LDLR), changes in cell adhesion and communication (LSAMP, TM4SF4, EFNA5, TSPAN5, PLXNA2), and potential stress responses or proteolytic imbalances (CD68, BACE1). Further functional studies are needed to determine if these changes are drivers of the disease or adaptive responses.
• Further Validation: The findings warrant further experimental validation at the protein level using techniques such as flow cytometry, immunofluorescence, or spatial proteomics, to confirm surface expression and explore the functional consequences of their differential expression in human diabetic islets and relevant in vitro/in vivo models.

9. Analysis of Macrophage Condition-Specific Surfaceome Markers in Pancreatic Diabetes

[Analysis Visualization Results]...

Analysis Overview

This analysis aimed to identify condition-specific surfaceome markers in Macrophage cells from pancreatic single-cell RNA-seq data, comparing 'type2_diabetes', 'prediabetes', and 'non_diabetic' conditions. The plot_markers_and_expression_dot tool was used with stringent filtering criteria: markers had to be surfaceome-localized, show a significant fold change (FC > 1.75 for type 2 diabetes vs. non-diabetic), be expressed in at least 30% of cells in the test group, and be removed if common across 3 or more conditions. The goal was to identify up to 40 such markers per condition, providing insights into macrophage alterations in diabetes.

Visual Summary

The dot plot, titled "Macrophage condition-specific markers," presents the expression profile of identified surfaceome markers. Surprisingly, only one marker, labeled "MS17006," was identified and visualized.

• Marker Identification: MS17006 is the sole marker displayed, suggesting that under the applied stringent filtering criteria (including surfaceome specificity and removal of markers common to three or more groups), very few, if any, other markers met the thresholds for condition-specific differential expression in macrophages across the diabetes spectrum.
• Expression Pattern: For MS17006, a red rectangle is displayed, corresponding to a high mean expression level as indicated by the "Mean expression in group" color scale (red implies higher expression). The number "35" adjacent to the rectangle likely represents the fraction of cells in the group expressing this marker, indicating that 35% of the cells in the target macrophage group expressed MS17006.
• Condition Specificity: While the plot identifies MS17006 as a "condition-specific marker," the x-axis labels for specific conditions (e.g., type2_diabetes, prediabetes, non_diabetic) are absent in the provided visualization. Therefore, the exact condition (or comparison group) to which MS17006 is specifically upregulated cannot be determined directly from this plot. The legend does show the criteria used for non_diabetic_vs_others, prediabetes_vs_non_diabetic, and type2_diabetes_vs_non_diabetic, suggesting MS17006 was identified in one of these comparisons.

Biological Interpretation

The identification of a single putative surfaceome marker, MS17006, for macrophages in the context of Type 2 Diabetes and Prediabetes is notable, albeit limited by the marker's unknown identity.

1. Identity of MS17006: MS17006 is not a standard human gene symbol. Without knowing the actual gene or protein that MS17006 represents, it is not possible to describe its specific associated signaling pathways or biological mechanisms. This is a critical limitation for a detailed biological interpretation. It might be an internal identifier or a probe ID within the dataset.
2. Implications of a Single Surfaceome Marker:
   • Stringent Filtering: The limited number of identified markers (only one) suggests that the applied filtering criteria, particularly the surfaceome_only setting, the high fold-change cutoff (e.g., FC > 1.75), and the exclusion of markers common to multiple groups, are highly stringent. This indicates that macrophage surfaceome changes that are truly *unique* to a single diabetic condition and highly expressed are rare or subtle in this dataset.
   • Macrophage Heterogeneity in Pancreatic Diabetes: Macrophages are key immune cells involved in the pathogenesis of Type 2 Diabetes within the pancreatic microenvironment. They infiltrate islets, contributing to chronic low-grade inflammation, beta-cell dysfunction, and insulin resistance. Different macrophage subsets (e.g., M1-like pro-inflammatory vs. M2-like anti-inflammatory/reparative) exhibit distinct surface protein profiles that dictate their interactions and functions [1]. If MS17006 were identified, it would represent a potential marker for a specific macrophage subpopulation or activation state that is uniquely altered in one of the diabetic conditions.
   • Significance of Surfaceome: Surface proteins are crucial for cell-cell communication, antigen presentation, adhesion, and receptor-mediated signaling. A differential surfaceome marker would indicate altered communication or functional states of macrophages in diabetes.
3. Hypothetical Pathways (General Macrophage Markers): If MS17006 represented a known surface protein, its biological role would be explored based on its function. For example:
   • If it were a Toll-like receptor (TLR) (e.g., TLR2, TLR4), it would imply altered innate immune sensing and activation of NF-κB pathways, leading to pro-inflammatory cytokine production (e.g., TNF-α, IL-6), which contributes to insulin resistance and beta-cell apoptosis.
   • If it were a chemokine receptor (e.g., CCR2, CXCR4), it would suggest altered macrophage migration and recruitment to the pancreas, potentially in response to islet stress signals (e.g., CXCL10, CCL2).
   • If it were an adhesion molecule (e.g., ICAM1, VCAM1), it would indicate changes in macrophage interaction with other pancreatic cells (e.g., endothelial cells, islet cells) or extracellular matrix, influencing tissue remodeling and immune cell trafficking.
   • If it were a scavenger receptor (e.g., CD36, MARCO), it might imply altered lipid metabolism or efferocytosis by macrophages, both relevant to pancreatic lipotoxicity and inflammation in diabetes.

Clinical or Translational Implications

Given the unidentified nature of MS17006, direct clinical or translational implications are speculative. However, we can discuss the general potential of such a marker if its identity were known and validated.

1. Therapeutic Target Potential: Surfaceome markers are highly attractive therapeutic targets because they are accessible on the cell surface. If MS17006 were a functional surface protein specifically upregulated in macrophages in prediabetes or Type 2 Diabetes:
   • Modulation of Macrophage Function: Targeting MS17006 could offer a strategy to modulate pathogenic macrophage activity (e.g., reduce pro-inflammatory phenotype, enhance insulin sensitivity, protect beta-cells) without broadly immunosuppressing the patient.
   • Targeted Therapies: Therapeutic agents such as monoclonal antibodies, small molecule inhibitors, or antibody-drug conjugates could be developed to specifically block MS17006 function or deplete specific macrophage populations expressing it [2]. For instance, agents targeting macrophage migration (e.g., CCR2 antagonists) have been explored in metabolic diseases.
2. Diagnostic/Prognostic Biomarker Potential: A macrophage-specific surface marker associated with diabetes progression could serve as a biomarker for disease staging, risk assessment, or monitoring therapeutic response. This would require validation in patient samples, potentially through flow cytometry on circulating monocytes/macrophages or immunohistochemistry on pancreatic biopsies.
3. Required Further Characterization:
   • Marker Identification: The most critical next step is to identify the gene symbol corresponding to MS17006. This would involve consulting the full dataset's var metadata or source information if available.
   • Functional Validation: Once identified, the function of the protein encoded by MS17006 needs to be investigated in vitro using macrophage cell lines or primary macrophages under diabetic-like conditions (e.g., high glucose, high fat). In vivo studies using animal models of diabetes would be crucial to confirm its role in disease pathogenesis and its therapeutic potential.
   • Cell Type Specificity and Subtype Localization: Confirming MS17006 expression specifically on macrophages and potentially on specific macrophage subsets (e.g., M1 vs. M2) within the pancreas.
   • Protein Expression Confirmation: Validating mRNA expression at the protein level using techniques such as flow cytometry, immunofluorescence, or mass spectrometry.

In conclusion, while the identification of a single marker (MS17006) points to potential unique macrophage alterations in diabetes, its unknown identity currently limits specific biological interpretation and direct translational application. Future efforts must focus on identifying and validating this marker.

---

References:

1. Macrophages in Diabetes: Search PubMed for "macrophages pancreas diabetes" https://pubmed.ncbi.nlm.nih.gov/?term=macrophages+pancreas+diabetes
2. Surfaceome as Drug Targets: Search PubMed for "surfaceome therapeutic targets" https://pubmed.ncbi.nlm.nih.gov/?term=surfaceome+therapeutic+targets

10. Pancreatic Stellate Cell Surfaceome Markers in Type 2 Diabetes

[Analysis Visualization Results]...

Analysis Overview

This analysis identifies and visualizes surfaceome markers specifically expressed in Stellate cells from the pancreas, focusing on samples from individuals with Type 2 Diabetes. The dot plot displays the expression levels and prevalence of these markers across various samples classified under 'type2_diabetes', using 'non_diabetic' as the reference for marker identification. The objective is to identify potential cell-type-specific surface markers that could be implicated in the pathophysiology of Type 2 Diabetes and Prediabetes, and to explore their biological mechanisms and therapeutic potential.

Visual Summary

The dot plot illustrates the mean expression level (color intensity, ranging from white for low to dark red for high) and the fraction of cells expressing a given marker (dot size, larger dot for higher fraction) for eight surfaceome markers across multiple Stellate cell samples from individuals with Type 2 Diabetes. The samples are grouped under the 'type2_diabetes' condition, and the number of cells per sample is indicated by a bar chart on the right.

• MMP14 stands out as a highly and consistently expressed marker across the majority of type 2 diabetes samples. It shows dark red dots, indicating high mean expression, and large dot sizes, signifying a high fraction of Stellate cells expressing this marker.
• PAM and TNFRSF14 also show moderate to high expression and prevalence in several samples, though not as universally prominent as MMP14.
• CD68, GLMP, ITGAE, SPINT2, and SLC6A6 generally exhibit lower or more variable expression and cell fractions across the type 2 diabetes samples compared to MMP14. While present, their signal is less robust in this visualization.

The overall pattern suggests an altered surfaceome profile in pancreatic Stellate cells in type 2 diabetes, with MMP14 being a particularly strong candidate for further investigation.

Biological Interpretation

Pancreatic Stellate Cells (PSCs) play a crucial role in the normal pancreas by maintaining the extracellular matrix (ECM). In disease states, particularly chronic pancreatitis and diabetes, PSCs can become activated, leading to excessive ECM production and fibrosis, which contributes to islet dysfunction and insulin resistance PubMed Search: pancreatic stellate cells diabetes fibrosis. The identified surfaceome markers provide insights into the potential cellular mechanisms altered in Stellate cells during Type 2 Diabetes.

1. MMP14 (Matrix Metallopeptidase 14)
   • General Function & Mechanism: MMP14, also known as MT1-MMP, is a membrane-bound matrix metalloproteinase. It plays a critical role in degrading and remodeling the ECM, activating other MMPs (e.g., MMP2), and processing various signaling molecules GeneCards: MMP14.
   • Relevance to Pancreatic Stellate Cells (PSCs) in Pancreas: Activated PSCs are key drivers of pancreatic fibrosis. MMP14 expression in PSCs is often upregulated during activation, contributing to ECM turnover and disease progression, including desmoplasia in pancreatic cancer and fibrosis in chronic pancreatitis and diabetes PubMed Search: MMP14 pancreatic stellate cells fibrosis. Its role in degrading ECM components allows for cell migration and invasion, which are features of activated PSCs.
   • Role in Type 2 Diabetes/Prediabetes: In T2D, increased MMP14 activity in PSCs could contribute to the remodeling of the islet microenvironment, leading to islet fibrosis. This fibrosis impedes insulin secretion, reduces islet viability, and contributes to impaired glucose homeostasis.
   • Therapeutic Potential: Inhibiting MMP14 activity in PSCs could be a strategy to mitigate pancreatic fibrosis and improve islet function in T2D. Several MMP inhibitors have been explored in various fibrotic conditions, though specific MMP14 inhibitors for pancreatic fibrosis in diabetes are an active area of research.
2. CD68 (CD68 Molecule)
   • General Function & Mechanism: CD68 is a transmembrane glycoprotein primarily expressed by monocytes and macrophages, functioning in phagocytosis and antigen presentation UniProt: P34810 (CD68_HUMAN). While conventionally a macrophage marker, its expression can be observed in other cells under specific inflammatory or stress conditions.
   • Relevance to PSCs in Pancreas: The presence of CD68 as a surfaceome marker on Stellate cells, even at moderate levels, could indicate a phenotypic shift towards a more phagocytic or inflammatory state, or potentially reflect complex interactions with the immune microenvironment in the diabetic pancreas.
   • Role in Type 2 Diabetes/Prediabetes: While less direct than MMP14, if Stellate cells in T2D express CD68, it might suggest their involvement in immune responses, potentially engulfing cellular debris or interacting with macrophages, contributing to chronic inflammation.
   • Therapeutic Potential: Not a primary direct target for PSC-mediated fibrosis, but modulating inflammatory phenotypes could be considered.
3. PAM (Peptidylglycine Alpha-Amidating Monooxygenase)
   • General Function & Mechanism: PAM is a bifunctional enzyme essential for the biosynthesis of neuropeptides, catalyzing the amidation of glycine-extended precursors GeneCards: PAM.
   • Relevance to PSCs in Pancreas: PSCs are known to interact with the nervous system within the pancreas, and altered neuropeptide signaling can influence both islet function and PSC activation.
   • Role in Type 2 Diabetes/Prediabetes: Changes in neuropeptide processing via PAM in PSCs could modulate local neuro-insular communication, affecting glucose regulation and contributing to metabolic dysfunction.
   • Therapeutic Potential: Modulating neuropeptide processing or their receptors in the context of PSCs could be a novel therapeutic avenue, though the direct targeting of PAM in PSCs for T2D needs further exploration.
4. GLMP (Glycoprotein M6a)
   • General Function & Mechanism: GLMP is a neuronal glycoprotein, involved in cell adhesion and membrane trafficking, often associated with neuronal plasticity GeneCards: GLMP.
   • Relevance to PSCs in Pancreas: PSCs, particularly in their quiescent state, share some features with neural cells. The expression of a neuronal glycoprotein like GLMP could signify an altered cellular identity or specific interactions with the pancreatic nervous system in the diabetic context.
   • Role in Type 2 Diabetes/Prediabetes: Alterations in GLMP expression might indicate disrupted neuro-stellate communication or a shift in PSC phenotype that could indirectly contribute to the pathological changes seen in T2D.
   • Therapeutic Potential: Less established as a direct target for T2D, but understanding its role could open new avenues in modulating neuro-pancreatic interactions.
5. ITGAE (Integrin Subunit Alpha E)
   • General Function & Mechanism: ITGAE (also known as CD103) forms a heterodimer with ITGB7 to create the E-cadherin-binding integrin αEβ7, primarily involved in immune cell homing and adhesion to epithelial cells UniProt: P38570 (ITA_HUMAN).
   • Relevance to PSCs in Pancreas: PSCs interact extensively with their microenvironment, including other cells and the ECM, often mediated by integrins. Expression of ITGAE on PSCs could indicate specific adhesive properties, potentially involving interactions with epithelial cells or immune cells.
   • Role in Type 2 Diabetes/Prediabetes: Altered integrin expression on PSCs in T2D could influence their adhesion, migration, and interaction with immune cells (e.g., T cells), contributing to chronic inflammation and fibrosis within the islet.
   • Therapeutic Potential: Targeting integrin pathways to disrupt pathological cell adhesion or migration of activated PSCs could be a strategy to reduce fibrosis and inflammation in T2D.
6. SPINT2 (Serine Peptidase Inhibitor, Kunitz Type 2)
   • General Function & Mechanism: SPINT2 is an inhibitor of various serine proteases, crucial for regulating proteolytic cascades involved in coagulation, inflammation, and tissue remodeling GeneCards: SPINT2.
   • Relevance to PSCs in Pancreas: Protease activity is integral to ECM turnover and inflammatory processes driven by activated PSCs. SPINT2 could modulate the balance of protease activity in the pancreatic microenvironment.
   • Role in Type 2 Diabetes/Prediabetes: Upregulation of SPINT2 in PSCs could suggest an attempt to counteract excessive proteolytic activity, or it might indicate altered regulation of protease-mediated signaling pathways contributing to the diabetic pathology.
   • Therapeutic Potential: Modulating protease inhibitor levels could impact pancreatic remodeling and inflammation, but the specific role and targeting of SPINT2 in T2D-related PSC activation require further investigation.
7. SLC6A6 (Solute Carrier Family 6 Member 6)
   • General Function & Mechanism: SLC6A6 is a high-affinity transporter for taurine, a sulfur-containing amino acid with osmoregulatory, antioxidant, and anti-inflammatory properties UniProt: O00341 (TAUT_HUMAN).
   • Relevance to PSCs in Pancreas: Taurine has protective effects against oxidative stress and inflammation, both of which are prominent in activated PSCs in the diabetic pancreas. Altered taurine transport via SLC6A6 could affect intracellular taurine levels and, consequently, PSC function.
   • Role in Type 2 Diabetes/Prediabetes: Dysregulation of taurine transport in PSCs could impair their ability to cope with oxidative stress and inflammation, exacerbating their activation and fibrogenic activity in T2D.
   • Therapeutic Potential: Enhancing taurine uptake or providing taurine supplementation in a cell-specific manner could be a strategy to protect PSCs from damage and inhibit their pathological activation, potentially improving pancreatic health in diabetes.
8. TNFRSF14 (TNF Superfamily Receptor 14)
   • General Function & Mechanism: TNFRSF14 (also known as HVEM) is a member of the TNF receptor superfamily, interacting with various ligands to regulate immune responses, cell survival, and apoptosis GeneCards: TNFRSF14.
   • Relevance to PSCs in Pancreas: PSCs are responsive to inflammatory signals, and TNFRSF14 could mediate their response to inflammatory cytokines, influencing their activation status and survival.
   • Role in Type 2 Diabetes/Prediabetes: In the inflammatory environment of the diabetic pancreas, TNFRSF14 on PSCs could contribute to chronic inflammation or influence PSC survival pathways, thereby impacting the progression of fibrosis and islet dysfunction.
   • Therapeutic Potential: Modulating TNFRSF14 signaling could offer a way to control inflammatory responses or reduce PSC activation and proliferation in T2D. Targeting TNF superfamily pathways is a recognized approach in inflammatory diseases.

Clinical or Translational Implications

The identification of surfaceome markers on pancreatic Stellate cells in Type 2 Diabetes samples provides crucial insights for potential diagnostic and therapeutic applications.

• Diagnostic Biomarkers: Highly expressed surface markers like MMP14 could serve as biomarkers for activated Stellate cells, potentially indicating the severity of pancreatic fibrosis or disease progression in Type 2 Diabetes. Their detection through advanced imaging techniques or biopsies could inform clinical management.

Therapeutic Targets:

• MMP14 represents a promising therapeutic target to inhibit pancreatic fibrosis. Strategies could include specific MMP14 inhibitors to reduce ECM degradation and subsequent fibrotic remodeling, aiming to preserve islet architecture and function.
• Integrins (ITGAE) are well-established targets for modulating cell adhesion and migration. Developing specific inhibitors that target ITGAE on PSCs could prevent their activation, migration, and fibrogenic activity.
• TNFRSF14 opens avenues for modulating inflammatory responses within the pancreas. Therapeutics that block or agonize TNFRSF14, depending on its specific role in PSC activation and survival, could mitigate chronic inflammation in the diabetic pancreas.
• SLC6A6 suggests a metabolic intervention angle. Modulating taurine transport could enhance the protective capacity of PSCs against oxidative stress and inflammation, potentially through dietary or pharmacological approaches that increase taurine availability or transport efficiency.

• Drug Repurposing: Understanding these surfaceome markers may facilitate drug repurposing efforts for T2D. Existing drugs that target similar pathways in other fibrotic or inflammatory conditions could be evaluated for their efficacy in modulating PSC activity in diabetes.

Further validation through *in vitro* functional assays, animal models of diabetes, and eventually human clinical trials would be necessary to confirm the therapeutic utility of targeting these specific surfaceome markers on pancreatic Stellate cells.

11. Gene Ontology (GSA) Analysis of Beta Cells Across Diabetes Conditions

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates Gene Ontology (GO) biological processes and pathways enriched in Beta cells from individuals with prediabetes and type 2 diabetes, compared to non-diabetic controls. A separate comparison is also performed for non-diabetic Beta cells against all other conditions combined. The results focus on pathways associated with up-regulated differentially expressed genes (DEGs) in each comparison. This provides insight into the molecular shifts occurring in Beta cells during the progression of diabetes.

Visual Summary

The provided bar plots display the top enriched Gene Ontology (GO) terms for Beta cells based on up-regulated DEGs, across three comparisons:

1. Beta cell: non_diabetic_vs_others: Non-diabetic Beta cells compared to a combined group of prediabetic and type 2 diabetic Beta cells. Highly enriched terms include "Pathways of neurodegeneration" (Alzheimer, Parkinson, Huntington, ALS), "Prion disease", "Protein processing in endoplasmic reticulum", "Proteasome", and various metabolic pathways (e.g., "Valine, leucine and isoleucine degradation"). This suggests active protein quality control and cellular maintenance mechanisms in healthy Beta cells.
2. Beta cell: prediabetes_vs_non_diabetic: Prediabetic Beta cells compared to non-diabetic Beta cells. The most striking enrichments are for terms directly related to diabetes, such as "Type I Diabetes mellitus", "Maturity onset diabetes of the young", and "Type II Diabetes mellitus". Other significant pathways include "MAPK signaling pathway", "cAMP signaling pathway", "mTOR signaling pathway", "PI3K-Akt signaling pathway", "HIF-1 signaling pathway", and "Pathways of neurodegeneration". This indicates a clear molecular shift towards a disease state, involving key metabolic and stress-response signaling cascades.
3. Beta cell: type2_diabetes_vs_non_diabetic: Type 2 diabetic Beta cells compared to non-diabetic Beta cells. This plot shows highly significant enrichment (very high -log(p-val) and -log(q-val)) for fundamental cellular processes and stress responses. Top terms include "Ribosome", "Oxidative phosphorylation", "Non-alcoholic fatty liver disease", "Lysosome", "Thermogenesis", "Amyotrophic lateral sclerosis", "Spliceosome", "Proteasome", "Pathways of neurodegeneration" (Parkinson, Alzheimer, Prion disease), "Ubiquitin mediated proteolysis", "Insulin signaling pathway", "Autophagy", and "mTOR signaling pathway". This suggests profound metabolic stress, protein quality control challenges, and a strong overlap with neurodegenerative disease mechanisms in type 2 diabetic Beta cells.

Biological Interpretation

The Gene Ontology analysis highlights distinct biological processes underpinning Beta cell function and dysfunction in diabetes progression.

• Healthy Beta Cell Homeostasis (non_diabetic_vs_others): The enrichment of "Protein processing in endoplasmic reticulum" and "Proteasome" in non-diabetic Beta cells suggests robust protein quality control mechanisms are active under healthy conditions. Pathways of "neurodegeneration" may reflect shared molecular machinery involved in managing cellular stress and protein aggregation, which could be protective in non-diabetic states.
  • For further reading on protein quality control in Beta cells: PubMed search: protein quality control beta cell function
• Early Disease Signature in Prediabetes (prediabetes_vs_non_diabetic): The direct upregulation of terms like "Type II Diabetes mellitus" pathways in prediabetic Beta cells indicates the onset of disease-specific molecular changes. The involvement of major signaling pathways such as MAPK, cAMP, mTOR, and PI3K-Akt suggests altered cellular proliferation, survival, and metabolic sensing. HIF-1 signaling could point to early signs of hypoxia or metabolic stress, while "Pathways of neurodegeneration" re-emerge, suggesting that stress mechanisms that might be protective in non-diabetic cells become overwhelmed or dysregulated in prediabetes. The term "Non-alcoholic fatty liver disease" also indicates a connection to broader systemic metabolic dysregulation impacting Beta cell health.
  • For information on mTOR signaling in diabetes: GeneCards: MTOR
• Profound Stress and Dysfunction in Type 2 Diabetes (type2_diabetes_vs_non_diabetic): Beta cells in type 2 diabetes exhibit severe metabolic and proteotoxic stress.
  • Metabolic Overload: High enrichment of "Ribosome" and "Oxidative phosphorylation" suggests increased protein synthesis and energy demands, potentially contributing to oxidative stress. "Non-alcoholic fatty liver disease" indicates continued lipid dysregulation.
  • Protein Homeostasis Failure: Strong enrichment of "Lysosome", "Proteasome", "Protein processing in endoplasmic reticulum", and "Ubiquitin mediated proteolysis" points to a substantial burden of misfolded proteins and damaged organelles, a hallmark of Beta cell failure in T2D. This is often associated with ER stress.
  • Neurodegeneration Parallels: The highly significant upregulation of multiple "Pathways of neurodegeneration" (Alzheimer, Parkinson, Prion disease, Amyotrophic lateral sclerosis) strongly suggests common cellular mechanisms of protein aggregation, misfolding, and cellular stress that lead to Beta cell demise in diabetes, akin to neuronal loss in these neurological disorders.
  • Signaling Dysregulation: "Insulin signaling pathway" enrichment in up-regulated genes could reflect compensatory responses or a shift to an altered, potentially dysfunctional, signaling state. "mTOR signaling pathway" and "Autophagy" are critical for nutrient sensing and cellular recycling, and their dysregulation is known to impact Beta cell survival.
  • For details on ER stress in Beta cells: PubMed search: ER stress beta cell diabetes

Clinical or Translational Implications

These findings have several potential clinical and translational implications:

• Biomarker Discovery: The identified pathways and their constituent genes could serve as potential biomarkers for early detection of Beta cell dysfunction in prediabetes or for monitoring disease progression in T2D.
• Therapeutic Targets: The highly enriched pathways, particularly those related to protein quality control (ER processing, proteasome, autophagy), oxidative phosphorylation, and specific signaling cascades (mTOR, PI3K-Akt, MAPK), represent promising therapeutic targets for preserving Beta cell function and mass in individuals with prediabetes and T2D.
• Repurposing Drugs: The strong overlap with "Pathways of neurodegeneration" suggests that drugs developed for neurodegenerative diseases targeting protein aggregation, ER stress, or mitochondrial dysfunction might be repurposed or adapted for Beta cell protection in diabetes.
• Understanding Disease Progression: The distinct pathway enrichments across non-diabetic, prediabetic, and T2D states provide a molecular roadmap of Beta cell pathology, helping to understand the progression from compensated function to overt failure. This knowledge can inform the timing and strategy for interventions.

12. Gene Set Enrichment Analysis Reveals Cell Type-Specific Metabolic and Inflammatory Dysregulation in Pancreatic Cells of Prediabetes and Type 2 Diabetes

[Analysis Visualization Results]...

Analysis Overview

This analysis presents Gene Set Enrichment Analysis (GSEA) results as a dot plot, illustrating pathway activity changes across various pancreatic cell types under different disease conditions. The analysis compares gene expression profiles in prediabetes and type 2 diabetes against a non-diabetic reference group, as well as the non-diabetic group against all other conditions combined. The results are displayed for nine key pancreatic cell types: Acinar cell, Alpha cell, Beta cell, Delta cell, Ductal cell, Endothelial cell, Gamma (PP) cell, Macrophage, and Stellate cell. Each dot represents a specific gene set (pathway), with its color indicating the Normalized Enrichment Score (NES) – red for positive NES (upregulated/activated), blue for negative NES (downregulated/inhibited) – and its size reflecting the statistical significance (-log(P)) of the enrichment. A total of 120 gene sets are shown.

Visual Summary

The dot plot provides a comprehensive visualization of cell type-specific pathway alterations in the pancreas.

• Axis Interpretation: The y-axis lists 120 distinct KEGG pathways. The x-axis represents comparisons for each cell type: celltype: prediabetes_vs_non_diabetic, celltype: type2_diabetes_vs_non_diabetic, and celltype: non_diabetic_vs_others.
• Color and Size Encoding: Red dots indicate pathways that are significantly upregulated or activated in the test condition compared to the reference, while blue dots represent downregulated or inhibited pathways. The size of each dot signifies the statistical significance, with larger dots corresponding to smaller p-values.
• General Trends: There is a clear increase in the number and significance of altered pathways in type 2 diabetes compared to prediabetes across most cell types. Many pathways related to metabolism, protein processing, and stress responses, such as 'Oxidative phosphorylation', 'Protein processing in endoplasmic reticulum', and 'Ribosome', are frequently upregulated across non-immune pancreatic cells in type 2 diabetes. Conversely, pathways like 'Fatty acid degradation' often show downregulation.

Cell Type-Specific Profiles:

• Beta cells show the most extensive and highly significant changes, particularly in type 2 diabetes, with strong upregulation of 'Insulin secretion', 'Oxidative phosphorylation', ER stress pathways, and 'Apoptosis'.
• Macrophages exhibit a distinct inflammatory signature, with strong upregulation of immune-related pathways like 'Phagosome', 'Lysosome', and 'TNF signaling pathway', alongside a unique downregulation of 'Oxidative phosphorylation'.
• Alpha cells show interesting bidirectional changes in 'Insulin secretion' pathway activity and consistent downregulation of the 'Glucagon signaling pathway' in prediabetes and type 2 diabetes.

• Non-Diabetic State Characteristics: The non_diabetic_vs_others columns show pathways characteristic of the non-diabetic state. For example, some pathways might appear upregulated (red) in non-diabetic cells, indicating their suppression in disease states, or vice versa.

Biological Interpretation

These GSEA results offer deep insights into the molecular mechanisms underlying pancreatic dysfunction in prediabetes and type 2 diabetes.

Beta Cell Dysfunction and Stress Response:

• The prominent upregulation of the 'Insulin secretion' pathway in Beta cells in both prediabetes and type 2 diabetes suggests an initial compensatory hypersecretion, which becomes more pronounced and potentially dysregulated in overt diabetes. This could reflect the sustained demand on Beta cells to produce more insulin in the face of peripheral insulin resistance. PubMed Search: beta cell hypersecretion type 2 diabetes
• Strong upregulation of 'Oxidative phosphorylation' points to increased metabolic workload or mitochondrial dysfunction within Beta cells, which can contribute to oxidative stress.
• The activation of 'Protein processing in endoplasmic reticulum' and 'Proteasome' pathways signifies significant Endoplasmic Reticulum (ER) stress, a key factor in Beta cell dysfunction and apoptosis in diabetes. PubMed Search: ER stress beta cell diabetes
• The upregulation of 'Apoptosis' pathway in type 2 diabetic Beta cells confirms accelerated cell death, leading to a reduction in functional Beta cell mass, a hallmark of progressive diabetes. PubMed Search: beta cell apoptosis type 2 diabetes
• Downregulation of 'Fatty acid degradation' in Beta cells suggests impaired lipid metabolism, which can exacerbate lipotoxicity and contribute to Beta cell failure.

Alpha Cell Dysregulation:

• The consistent downregulation of the 'Glucagon signaling pathway' in Alpha cells during prediabetes and type 2 diabetes is a notable finding. Despite hyperglucagonemia often observed in T2D, this may indicate desensitization or altered intracellular signaling within Alpha cells.
• The complex pattern in the 'Insulin secretion' pathway (downregulated in prediabetes, then upregulated in type 2 diabetes in Alpha cells) might reflect changes in general secretory machinery or calcium homeostasis, which are shared for both insulin and glucagon release.

Pancreatic Inflammation driven by Macrophages:

• Macrophages in type 2 diabetic pancreata display a highly activated and inflammatory phenotype. Pathways such as 'Phagosome', 'Lysosome', 'Antigen processing and presentation', and key inflammatory signaling pathways like 'TNF signaling pathway', 'NOD-like receptor signaling pathway', and 'IL-17 signaling pathway' are strongly upregulated. This highlights the crucial role of immune cell infiltration and chronic inflammation in promoting islet dysfunction and Beta cell damage in T2D. PubMed Search: macrophage pancreatic inflammation type 2 diabetes
• The unique downregulation of 'Oxidative phosphorylation' in macrophages in T2D, contrasting with other pancreatic cells, may suggest a metabolic shift towards glycolysis, characteristic of a pro-inflammatory (e.g., M1-like) macrophage phenotype.

Widespread Pancreatic Cell Stress and Remodeling:

• Beyond the islets, Acinar, Ductal, Endothelial, and Stellate cells also show significant pathway alterations in type 2 diabetes, often involving 'Oxidative phosphorylation', 'Protein processing in endoplasmic reticulum', and 'Ribosome' upregulation. This indicates a broader cellular stress response affecting the entire pancreatic microenvironment.
• Upregulation of 'Cell cycle' and 'DNA replication' in Acinar, Beta, Endothelial, and Stellate cells may signify attempts at compensatory proliferation, tissue repair, or pathological remodeling processes like fibrosis, particularly relevant for activated pancreatic stellate cells.

Clinical or Translational Implications

These findings provide a molecular foundation for understanding diabetes pathogenesis and suggest potential avenues for clinical translation.

• Targeted Therapeutic Interventions: The cell type-specific pathway enrichments can guide the development of targeted therapies. For example, interventions aimed at mitigating ER stress and apoptosis in Beta cells, or suppressing the pro-inflammatory phenotype of macrophages, could be beneficial.
• Biomarker Identification: Specific pathway signatures, such as ER stress markers in Beta cells or inflammatory pathway activation in macrophages, could serve as novel biomarkers for diagnosing early disease, monitoring progression, or evaluating therapeutic responses.
• Understanding Disease Progression: The distinct pathway changes observed between prediabetes and type 2 diabetes offer insights into the molecular events driving disease progression, allowing for the identification of critical windows for early intervention.
• Multi-cellular Approach: The widespread cellular stress across multiple pancreatic cell types underscores the importance of considering the entire pancreatic microenvironment, not just Beta cells, when developing comprehensive treatment strategies for diabetes.

13. Discussion

The comprehensive single-cell analysis of human pancreatic tissue reveals a complex landscape of cellular adaptations and dysfunctions associated with Type 2 Diabetes and Prediabetes. A fundamental insight is that while major cell type identities are largely preserved, disease progression is characterized by profound molecular shifts within these existing cell populations, rather than the emergence of entirely new cell types.

Pancreatic Beta cells, central to glucose homeostasis, exhibit extensive evidence of metabolic and proteotoxic stress, including robust activation of ER stress and oxidative phosphorylation pathways, and a strong upregulation of apoptosis. The consistent enrichment of 'Pathways of neurodegeneration' among up-regulated genes in diabetic Beta cells is particularly striking, suggesting shared underlying mechanisms of protein aggregation, misfolding, and cellular demise, similar to those seen in neurological disorders. Furthermore, alterations in surfaceome markers such as the downregulation of FFAR4 (free fatty acid receptor) and upregulation of LDLR (low-density lipoprotein receptor), EFNA5, and PLXNA2 highlight a dysregulation in lipid sensing, uptake, and cell-cell adhesion, contributing to lipotoxicity and impaired communication within the islet. Notably, Alpha cells show a consistent downregulation of the 'Glucagon signaling pathway' in both prediabetes and type 2 diabetes, a finding that, despite common hyperglucagonemia in T2D, suggests an intracellular desensitization or altered signaling within alpha cells rather than simply increased activity.

Immune dysregulation plays a critical role, with pancreatic macrophages demonstrating a clear and progressive shift towards a pro-inflammatory M1 phenotype in prediabetes and type 2 diabetes. This is evidenced by an increasing proportion of M1 macrophages and a decrease in M2C/M2D subsets, corroborated by GSEA showing upregulation of inflammatory pathways like 'TNF signaling pathway' and a distinct downregulation of 'Oxidative phosphorylation' – a metabolic signature characteristic of M1-like macrophages. This shift underscores the persistent chronic inflammation driving islet dysfunction and Beta cell damage. Pancreatic stellate cells also contribute to the pathological remodeling of the pancreas, with the upregulation of MMP14, a key fibrogenic matrix metalloprotease, indicating active extracellular matrix degradation and subsequent fibrosis in T2D. Other surface markers like ITGAE and TNFRSF14 suggest altered adhesion and inflammatory responses within the stromal compartment.

Intercellular communication is significantly altered across disease states. Pervasive integrin-mediated interactions with extracellular matrix components highlight ongoing tissue remodeling. A novel finding is the intensification of the LCN2-SLC2A1 axis in diabetic conditions, particularly between Beta/Delta and Ductal cells, suggesting a critical link between inflammatory stress and altered glucose metabolism. Furthermore, condition-specific cell-cell interaction analysis revealed strong activation of BMP5-receptor and Desmosterol-NR1H2 (LXRB) signaling among Beta, Ductal, and Delta cells in type 2 diabetes, pointing to dysregulated proliferation, differentiation, and lipid metabolism. Conversely, beneficial WNT4 signaling interactions observed between Beta and Ductal cells in non-diabetic samples appear attenuated in prediabetes, potentially contributing to early Beta cell decline. Overall, these findings reveal a coordinated, multi-cellular response involving immune, stromal, and endocrine cells that contributes to pancreatic dysfunction in diabetes, providing critical insights beyond simple Beta cell failure.

Hypotheses:

1. Chronic ER stress, oxidative stress, and impaired protein quality control, leading to apoptosis, are central mechanisms of Beta cell failure in Type 2 Diabetes, partially driven by altered lipid handling and inflammatory signals.
2. A pathological shift towards a pro-inflammatory M1 macrophage phenotype in the pancreatic microenvironment contributes significantly to islet inflammation and Beta cell damage in Type 2 Diabetes.
3. Activation of pancreatic stellate cells and upregulation of enzymes like MMP14 drive pathological extracellular matrix remodeling and fibrosis, impairing islet function and aggravating diabetes progression.
4. Dysregulated LCN2-SLC2A1, BMP5-receptor, and Desmosterol-NR1H2 (LXRB) signaling pathways mediate critical maladaptive cell-cell interactions within the islets and between islets and ductal/stromal cells, contributing to progressive Beta cell dysfunction and remodeling in Type 2 Diabetes.
5. Attenuation of protective WNT signaling in prediabetes contributes to early Beta cell mass and function decline, indicating a failure of regenerative or homeostatic mechanisms.

Potential therapeutic targets:

1. FFAR4 (Free Fatty Acid Receptor 4): Reduced FFAR4 expression in diabetic Beta cells may contribute to impaired glucose-stimulated insulin secretion (GSIS) and increased inflammation. Activating FFAR4 could restore Beta cell function and survival, and reduce inflammation. Evidence: Section 8 shows FFAR4 is higher in non-diabetic Beta cells and lower in T2D Beta cells. FFAR4 is a GPCR that senses long-chain fatty acids, enhancing GSIS, Beta cell proliferation, and mediating anti-inflammatory effects. Validation: Test FFAR4 agonists in vitro on human diabetic Beta cells for improved insulin secretion, proliferation, and reduced inflammatory marker expression. Evaluate in vivo efficacy in relevant animal models of diabetes.
2. MMP14 (Matrix Metallopeptidase 14): Highly upregulated in activated pancreatic stellate cells in Type 2 Diabetes, MMP14 is a key driver of extracellular matrix (ECM) degradation and fibrotic remodeling, which impairs islet function. Inhibiting MMP14 could mitigate pancreatic fibrosis. Evidence: Section 10 shows MMP14 as a highly and consistently expressed surfaceome marker in Stellate cells from type 2 diabetic samples. It plays a critical role in ECM remodeling and fibrosis in chronic pancreatitis and diabetes. Validation: Develop and test specific MMP14 inhibitors in models of pancreatic fibrosis and diabetes, assessing their impact on ECM deposition, islet architecture, Beta cell function, and glucose homeostasis.
3. LCN2-SLC2A1 axis: The observed intensification of LCN2-SLC2A1 interactions in prediabetes and Type 2 Diabetes, particularly between Beta/Delta and Ductal cells, suggests a pathological link between inflammatory stress and altered glucose metabolism. Blocking this axis could mitigate Beta cell dysfunction and inflammation. Evidence: Section 6 highlights the increased log2(mean) expression of LCN2_SLC2A1 interactions, e.g., Delta|Ductal and Beta|Ductal, with disease progression. LCN2 is an inflammatory protein linked to insulin resistance and β-cell dysfunction. Validation: Investigate the effect of blocking LCN2 or SLC2A1, or their interaction, using genetic or pharmacological approaches in co-culture systems (e.g., Beta-ductal cells) and in vivo diabetes models. Assess impact on glucose metabolism, inflammation, and Beta cell health.
4. LXRB (Liver X Receptor beta) / Desmosterol-NR1H2 pathway: Strong activation of Desmosterol-NR1H2 (encoding LXRB) interactions in Type 2 Diabetic Beta, Ductal, and Delta cells indicates altered lipid metabolism and potential lipotoxicity, central to T2D pathology. Modulating LXRB activity could improve lipid homeostasis and reduce lipotoxicity. Evidence: Section 7 reveals highly active Desmosterol_byDHCR7_NR1H2 interactions in type 2 diabetic samples among Beta, Ductal, and Delta cells. LXRB plays a key role in lipid and glucose metabolism, responding to oxysterols like desmosterol. Validation: Develop or repurpose selective LXRB modulators (agonists or antagonists). Test their effect on lipid accumulation, inflammation, and insulin secretion in diabetic islet cells and in vivo models of diabetes, while addressing potential side effects like hepatic steatosis.
5. Macrophage M1 polarization pathways (e.g., TNF signaling components): The shift towards a pro-inflammatory M1 macrophage phenotype in the diabetic pancreas drives chronic inflammation and Beta cell damage. Dampening M1 activation could protect islets and improve insulin sensitivity. Evidence: Section 5 shows increasing M1 macrophage proportion and decreasing M2C/M2D in diabetes. Section 12 (GSEA) reveals upregulation of 'TNF signaling pathway', 'NOD-like receptor signaling pathway', and 'IL-17 signaling pathway' in T2D macrophages. Validation: Utilize inhibitors targeting specific M1-promoting signaling molecules (e.g., NF-κB, specific TLRs, TNFα) in isolated pancreatic macrophages in vitro and in vivo diabetes models. Assess their impact on inflammatory cytokine production, macrophage phenotype, and Beta cell function/survival.

Follow-up validation ideas:

1. Perform in vitro perturbation assays on human or murine pancreatic islet cells (Beta, Alpha), macrophages, and stellate cells under diabetic-like conditions. Perturb identified targets (e.g., FFAR4, LDLR, MMP14, BMP/LXR pathways) using agonists/antagonists or gene editing (CRISPR), and measure insulin secretion, apoptosis, proliferation, inflammatory markers, and fibrotic gene expression.
2. Utilize diet-induced or genetic animal models of diabetes to apply pharmacological inhibitors or genetic manipulations (e.g., conditional knockouts) for key targets (MMP14, LCN2, LXRB, specific BMP receptors, FFAR4). Assess changes in glucose homeostasis, beta cell mass, islet morphology, inflammation, and fibrosis.
3. Conduct spatial transcriptomics or proteomics on human diabetic pancreatic tissues to validate colocalization and functional interactions of identified ligand-receptor pairs (e.g., LCN2-SLC2A1, BMP5-receptor, Desmosterol-LXR) and surface markers (e.g., MMP14 on stellate cells, FFAR4 on Beta cells) in situ.
4. Validate protein expression of candidate surface markers (e.g., FFAR4, LDLR, EFNA5, MMP14, ITGAE, TNFRSF14) on isolated pancreatic cell types or tissue sections from diabetic patients and controls using multi-color flow cytometry or immunofluorescence.
5. Analyze pancreatic tissue biopsies or circulating biomarkers (e.g., LCN2, soluble receptors/ligands) from larger human cohorts with varying stages of diabetes to correlate identified molecular changes with clinical parameters and disease progression.
6. Establish cell-cell co-culture assays with specific pancreatic cell types (e.g., Beta cells with activated stellate cells, or Beta cells with M1/M2 macrophages) to study the functional impact of identified cell-cell interactions (e.g., SPP1-integrin, TGFBI-TGFBR) on Beta cell survival, proliferation, and function.

Limitations:

This report is based on a cross-sectional single-cell RNA-seq dataset, which inherently limits direct inference of causality and disease progression over time. Observed changes represent snapshots of transcriptional states rather than dynamic processes. While efforts were made to control for batch effects, residual technical variability might exist. Interpretations of protein-level changes and functional consequences are inferred from mRNA expression and require validation via orthogonal methods like proteomics, flow cytometry, or functional assays. The reliance on known ligand-receptor pairs for cell-cell interaction analysis may overlook novel or less characterized interactions. The presence of 'unassigned' cells and unidentified markers (e.g., MS17006) indicates areas of remaining uncertainty in cellular annotation. Finally, while potential therapeutic targets are identified, their translation to clinical practice necessitates extensive preclinical and clinical trials.

14. Query List

1. Show and save UMAPs for condition, sample, major cell type, minor cell type, and celltype_subset in two columns.
2. Show major cell type scores on UMAP and save the result.
3. Show and save a marker expression dot plot for celltype_subset. SET target_cell = None and var_group_rotation = 45. Leave all other arguments at their default values.
4. Show and save a population bar plot of minor cell types.
5. Show and save a population bar plot of macrophage subsets.
6. Show and save cell-cell interaction patterns. Select at most 80 cell-cell interactions per group.
7. Find cell-cell interactions involving major tissue cells, immune cells and stromal cells that differ significantly between conditions, show them as a dot plot, and save the result. Set max_n_items_per_group to 60. For each interaction identified under each condition, using the provided dataset context, describe the associated signaling pathways and mechanisms and, where relevant, its potential as a therapeutic target and related therapeutic agents.
8. Show Beta cell marker expression in a dot plot, and save the result. Use only surfaceome markers, with at most 50 markers per condition. For each marker identified under each condition, using the provided dataset context, describe the associated signaling pathways and biological mechanisms within the Pancreas and, where relevant, its potential as a therapeutic target for type 2 diabetes and prediabetes and related therapeutic agents.
9. Show marker expressions for Macrophage in a dot plot, and save the result. Use only surfaceome markers, with at most 40 markers per condition. For each marker identified under each condition, using the provided dataset context, describe the associated signaling pathways and biological mechanisms within the Pancreas and, where relevant, its potential as a therapeutic target for type 2 diabetes and prediabetes and related therapeutic agents.
10. Show marker expressions for Stellate cell in a dot plot, and save the result. Use only surfaceome markers, with at most 40 markers per condition. For each marker identified under each condition, using the provided dataset context, describe the associated signaling pathways and biological mechanisms within the Pancreas and, where relevant, its potential as a therapeutic target for type 2 diabetes and prediabetes and related therapeutic agents.
11. Show Beta cell Gene Ontology (GSA) analysis results as a bar plot, and save the result.
12. Show Gene Set Enrichment Analysis results as a dot plot, and save it. Set the color map to RdBu_r, n_pws_to_show to 120, and target_cells to None.